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Abstract

In epidemiologic and clinical studies, a relatively large number of biomarkers are repeatedly
measured in patients over time, often associated with data on epidemiologic and clinical interest
events. So, much attention is focused on developing the specific patterns of the longitudinal measurements, and the associations between those patterns and the time to a certain event, such as heart
attack, diagnose of disease, time to transplantation, or death. In the last two decades, the research
into joint modeling of longitudinal and time-to-event data has received a tremendous amount of
attention.
Numerous researchers have proposed joint modeling approaches for a single longitudinal exposure and time-to-event data, herein referred to as univariate joint modeling. Those model-based
analyses may not provide robust inference when longitudinal measurements exhibit skewness
and/or heavy tails. Additionally, the collected data are often featured by multivariate longitudinal exposures, which are significantly correlated, and ignore their correlation may lead to biased
estimation. To the best of our knowledge, few studies focus on the multivariate joint modeling
(MVJM) with a skewed distribution for longitudinal responses to cope with correlated multiple
longitudinal exposures and adjust departures from normality and tailor linkage in specifying a
survival process.
This dissertation research contributes to the Bayesian inference statistical methodology in the
field of joint modeling analyses, which is applied to a type 1 diabetes (T1D) study and a primary
biliary cirrhosis (PBC) study. In this dissertation, firstly, we develop multivariate mixed-effects
joint modeling for skewed-longitudinal and time-to-event data with skew distribution; the associ-

v

ated Bayesian inferential approach is introduced; the proposed joint modeling is applied to analyze
the diabetes study data. Simulation studies are also conducted to assess the performance of the
proposed method under different scenarios. Secondly, a Bayesian trivariate linear mixed-effects
models with skew-normal distribution is applied to analyze Mayo Clinical PBC study data. This
biostatistical methodology can be widely used in epidemiological and clinical study. Our multivariate joint modeling can provide more precise information and evidence to physicians, benefiting
their treatment evaluation and clinical decision-making. All the analyses introduced in this dissertation have been implemented under the Bayesian framework, in the R and WinBUGS public and
freely available software environment. The software codes are available from the author upon
request.

vi

Chapter 1
Introduction and literature review

1.1

Introduction

Various clinical and observational studies, in addition to the participants are followed-up repeatedly
and response data are collected (e.g., weight, height, biomarkers), lifetime (time-to-event) data is
also recorded (e.g., heart attact, organ transplantation, diagnose of disease, death). The relationship
between longitudinal exposures and the time-to-event outcome is often of interest. For example, in
HIV/AIDS (human immunodeficiency virus) studies, as two essential biomarkers, repeatedly measured CD4 cell counts and viral load (the number of viral particles in each milliliter of blood) have
been broadly studied [46]. Modeling the longitudinal and event-time outcomes separately, the linear mixed-effects model has been considered as the classical model for longitudinal data analysis
[52] and the Cox proportional hazards model [19] for survival data are often adopted. It is referred
to as a separate analysis in many scientific research. These two types of data have common characters: (i) longitudinal measurement sequences are collected potentially and intermittently with
various variations and subject to measurement errors; (ii) occurrence of the time-to-event may or
may not eliminate the underlying longitudinal process, possibly in an informative approach; and
(iii) the hazard for time-to-event will be affected by the underlying longitudinal process. These
characters hint that if the two outcome processes are correlated, the separate analysis of longitudinal exposures and survival outcomes can lead to biased effect size estimates. A novel and
powerful method to remedy these deficiencies are joint modeling [78, 68]. The joint modeling, a
simultaneous approach to both processes (longitudinal and survival), can ensure that longitudinal
information is sufficiently incorporated into the survival model. To date, with the absence of an
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accessible introduction in the clinical literature hinders their broader adoption, the joint modeling
methods still remain underused.
1.2

Literature review of joint modeling

In the last two decades, the joint modeling of longitudinal and time-to-event data is one of the most
rapidly attractive areas of current biostatistics research [10, 37, 66, 69, 79]. In the medical research
field, this novel statistical method is the most practical. For example, during patient follow-up
studies after the surgery; to explore a personalized pattern of clinical visits; to develop predictions
of survival based on the evolution of the individual patient, or updating those predictions in light
of new data; identification of essential biomarkers; prediction of patient outcome with different
chronic diseases such as diabetes, some types of cancer or Alzheimer disease. The joint modeling
techniques allow for the simultaneous study of longitudinal and survival data. Longitudinal data
contains repeated measurements of different exposures for each individual over time, and time-toevent data represents the anticipated time before an event happens (e.g., an asthma crisis, death, a
transplant). That combination of data frequently arises in many scientific fields such as in clinical
research, biology and biomedical where statistical methods are adopted, where it is common to
analyze the evolution of a sick person over time.
The motivation behind this attractive statistical field has stemmed from the benefits of joint modeling: (i) Allow the simultaneous estimation of parameters from both the survival and longitudinal
processes; (ii) Combine these two data sets into a single joint model so that the dependence and
association between the time-to-event and longitudinal data to better assess the impact of exposures on the event can be inferred; (iii)Account for within-subject and between-subject variations,
correlation and measurement error in longitudinal exposures; (v)All information in longitudinal
and survival processes incorporated, simultaneously, to estimate all parameters; (iv) Reduce bias
in estimation and provide more accurate parameter estimates, compared to time-dependent Cox
model and two-stage model [23, 38, 83].
Previous research has for the most part focused on the joint modeling of a single longitudinal exposure and a single survival outcome; herein in reference to as univariate joint modeling
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(UVJM). However, the data collected will generally be more complicated in practice; multiple
longitudinal measurements and possibly multiple, recurrent or competing events will be recorded.
A pseudo-relationship between one longitudinal outcome and the survival outcome may be examined when ignoring other longitudinal outcomes. Consequently, a joint modeling approach with
multiple longitudinal outcomes is needed to characterize the interplay among different longitudinal exposures and the event process. For example, Ghosh and Rizopoulos [70] reported chronic
kidney disease data, all 407 patients underwent renal transplantation. Each individual patient had
recorded 3 separate biomarker measurements repeated: blood hematocrit level, proteinuria, and
glomerular filtration rate (GFR). With the clinical interest being the time to graft failure, each of
these biomarkers can be considered as a potential predictor of renal function. Combining all the
available information into a single model is beneficial and should provide the results to enhance
the model estimations and predictions. Therefore, this makes multivariate joint modeling (MVJM)
a captivating tool in recent statistical research of personalized medicine. The MVJM approaches
have the ability to produce more precise knowledge and evidence to physicians, decision-making
for individual patients at a specific follow-up time point and benefiting their clinical treatment
evaluation. The extension of the traditional UVJM framework to an MVJM framework increases
the flexibility and better predictive capability; however, it also introduces a number of technical
and computational challenges. The frequentist approaches are more complicated to perform when
the number of longitudinal biomarkers is large, because integrating over the vector of all random
effects to evaluate the joint likelihood of the multivariate longitudinal and survival data is required
for most of these frequentist approaches.
An MVJM generally consists of longitudinal sub-model and survival sub-model, they are the
multivariate mixed-effects model for longitudinal data and Cox proportional hazards model for
time-to-event data, respectively; the latent (random-effects) variables to bring these two data sets
together into a single model, so, the interplay and association between longitudinal and time-toevent data can be inferred. Multiple longitudinal/multi-dimensional exposures arise when multiple
biomarkers measured over time are to be evaluated for their prognostic values. Additionally, we
allow fixed effects in both the time-to-event and longitudinal sub-models, as well as deal with the
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difficulty in parameter estimation due to such additions. Hickey et al. [39] provide an excellent
review of the multivariate joint modeling and its software in 2016. Until recently, there is a lack
of general-purpose software available for fitting multivariate joint models. Since 2017, there have
been several developments in this area. Multiple longitudinal exposures joint modeling methods
were presented where all longitudinal exposures were continuous outcomes [16, 77, 15]. Hatfield
et al. [35] modelled the MVJM with Bayesian inference where longitudinal exposures were count
outcomes. He et al. [36] presented methods where the longitudinal exposures were a mix of data
types (e.g., continuous, ordinal and binary longitudinal outcomes).
1.3

Multivariate skew-normal distribution

Various versions of the multivariate skew distribution have been proposed and used in the literature
[4, 5, 6, 7, 49, 71]. A new class of distributions by introducing skewness in multivariate elliptically
distributions were developed in the literature [5, 71]. This class is acquired by using conditioning
and transformation, contains many standard families including the multivariate skew-normal (SN)
distributions as special cases. A k-dimensional random vector Y follows a k-variate skew-elliptical
(SE) distribution if its probability density function (pdf) is given by
f (y|µ, ⌃,
where A = ⌃ +
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nal) covariance matrix,

(k)

(k)

; m⌫ ) = 2k f (y|µ, A; m⌫ )P (V > 0),

(1.1)

, µ is a location parameter vector, ⌃ is a k ⇥ k positive (diagois a k ⇥ k diagonal skewness matrix

= diag( 1 , 2 , . . . ,

k)

with the skewness parameter vector
= ( 1 , 2 , . . . , k )T ; V follows the elliptical distribu⇣
⌘
(k)
(k)
tion El
A 1 (y µ), I k
A 1 ; m⌫
and the density generator function m⌫ (u) =
R 1 k/2 1
k/2 1 m (u)
⌫
R 1u
,
with
m
(u)
being
a
function
such
that
u
m⌫ (u)du exists. The function
⌫
k/2
1
0
u
m⌫ (u)du
0

m⌫ (u) provides the kernel of the original elliptical density and may depend on the parameter ⌫.
This SE distribution is denoted by SE(µ, ⌃,

(k)

; m⌫ ). One example of m⌫ (u), leading to impor-

tant special cases used throughout the paper, m⌫ (u) = exp( u/2). This expression lead to the
multivariate SN distribution.
As we know, a normal distribution is a special case of the SN distribution when the skewness
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parameter is zero. For completeness, this Appendix briefly summarizes the multivariate SN distributions introduced by Sahuet al.[71] to be suitable for a Bayesian inference since it is built using
the conditional method. Assume a k-dimensional random vector Y follows a k variate SN distribution with location vector µ, k ⇥ k positive (diagonal) covariance matrix ⌃ and k ⇥ k diagonal
skewness matrix

= diag( 1 , 2 , . . . ,

In what follows, we briefly discuss the multivariate

k ).

SN distributions introduced by Sahu et al.[71] to be suitable for a Bayesian inference since they
are built using the conditional method. Please see the Reference [71] for a detailed discussion on
properties of SN distributions.
A k-dimensional random vector Y follows a k-variate SN distribution, if its pdf is given by

) = 2k |A|

f (y|µ, ⌃,
where V ⇠ Nk { A 1 (y

1/2

µ), I k

the above distribution by SNk (µ, ⌃,

A

f (y|µ, ⌃,

)=

i=1

1/2

(y

}, and

1

(1.2)

µ)}P (V > 0),
k (·)

is the pdf of Nk (0, I k ). We denote

). An appealing feature of equation (1.2) is that it gives

independent marginal when ⌃ = diag( 12 ,
Qk

k {A



p

2
2, . . . ,

2
2
2
i+ i

⇢

2
k ).

The pdf (1.2) thus simplifies to

pyi 2 µi 2
i+ i

⇢

i
i

pyi 2 µi 2
i+ i

,

(1.3)

where (·) and (·) are the pdf and cdf of the standard normal distribution, respectively.
It can be easily shown that the mean and covariance matrix are given by E(Y ) = µ +
p
2/⇡ , cov(Y ) = ⌃ + (1 2/⇡) 2 . It is noted that when = 0, the SN distribution reduces to the standard normal distribution. In order to have a zero mean vector, we should assume
p
the location parameter µ =
2/⇡ .
According to the literature [4, 71], if Y follows SNk (µ, ⌃,

), it can be expressed by a conve-

nient stochastic representation as follows.
Y =µ+

|X 0 | + ⌃1/2 X 1 ,

(1.4)

where X 0 and X 1 are two independent Nk (0, I k ) random vectors. Let w = |X 0 |; then, w

follows a k-dimensional standard normal distribution Nk (0, I k ) truncated in the space w > 0.
Thus, a two-level hierarchical representation of (1.4) is given by
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Y |w ⇠ Nk (µ +
Note that when
SNk (µ, ⌃,
1.4

w, ⌃), w ⇠ Nk (0, I k )I(w > 0).

(1.5)

= 0, the hierarchical expression (1.5) presented for the SN distribution

) reduces to its counterpart for the normal distribution Nk (µ, ⌃).

Specific aims

Numerous researchers have proposed joint modeling approaches for a single longitudinal outcome
and single survival outcome [10, 37, 66, 69, 79]; herein referred to as univariate joint modeling.
There is also limited work on joint models for a few longitudinal measurements and survival data[1,
11, 14, 15, 59, 50, 63, 64, 70, 76]. However, when the number of longitudinal biomarkers is very
large, it is very difficult to implement these methods, since majority of these approaches require
integrating over the vector of all random effects to evaluate the joint likelihood of the time-toevent and multivariate longitudinal data. Additionally, there are few studies focusing on MVJM
for longitudinal and survival data with skewness assumptions. Such needs warrant extensive and
continued efforts to study the complicated longitudinal and survival data through the MVJM. This
research focuses on MVJM, and tries to present the following two particular questions:
• First, the joint modeling of time-to-event and longitudinal data has received a great deal
of attention in clinical research and epidemiological studies under a linear mixed-effects
model with normal assumption and Cox proportional hazards model with a single longitudinal outcome. However, those models-based approaches might not provide robust inference when longitudinal measurements exhibit skewness and/or heavy tails. Furthermore,
the data collected are often characterized by multivariate longitudinal outcomes which are
significantly correlated, and ignoring their correlation may lead to biased estimation. A
multivariate mixed-effects joint modeling (MVJM) with SN distribution for longitudinal
and time-to-event data and related statistical inference methods are required to better understand the different longitudinal exposures trajectories and the associations among these
longitudinal exposures and the survival time.
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• Second, the methodology and approach developed for the T1D analysis can be applied for
the analysis to a more general field in clinical practice when multivariate longitudinal measurements and time-to-event data are available. Especially, joint modeling approaches still
remain under-used, and the absence of an accessible introduction in the clinical and medical literature inhibits their wider adoption. In this spirit, the methodology proposed here
can be consumed for modeling the progression of rare diseases (primary biliary cirrhosis
study).
Under the Bayesian inference and assuming skew normal distribution, this dissertation research
is organized as follow:
• Aim 1. In Chapter 3, we explored the multivariate mixed-effects joint modeling for skewedlongitudinal and survival data with multiple longitudinal outcomes, and Bayesian inference
method is introduced; a real data set from pediatric diabetes study is used to present the
proposed models and simulation studies are conducted to validate the conclusions.
• Aim 2. In Chapter 4, we apply a Bayesian trivariate linear mixed-effects joint modeling
with SN distribution, to analyze Mayo Clinical Primary Biliary Cirrhosis study; and UVJM
with SN distribution and MVJM with normal dribution analyses are conducted as comparison.
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Chapter 2
Motivating datasets

2.1

Pediatric type 1 diabetes study

In our primary motivating example interest lies in exploring the relationship between growth trajectories (height, weight) as well as the risk of type 1 diabetes (T1D) for pediatric participants. T1D is
a common pediatric chronic disease and is preceded by a preclinical period of IA in the presence of
islet autoantibodies. The multicenter T1D data is a prospective multinational (U.S. Finland, Germany and Sweden) cohort study to investigate the environmental determinants of T1D [32, 56]. A
number of studies[26, 57, 9, 84] have looked into the relationship of T1D in the population with the
growth exposures and find that the growth in early childhood is linked to the risk of T1D. The following are the main findings of Body Mass Index (BMI) for association with T1D in these studies.
According to the US Diabetes Autoimmunity Study in the Young (DAISY) [53], the children from
the age of two to eleven, the Cox proportional hazards model is conducted to identify the growth
velocities for association with islet autoimmunity (IA) and T1D, it also finds that height growth
velocity in z-score is positively associated with IA development and T1D, but not weight and BMI
growth velocity in z-score. A cohort study of 548 Australian children followed from birth [18], the
data is analyzed by parametric survival model, and the finding suggests that both weight and BMI
z-score predict the risk of IA at two years but not in children with an increased genetic risk of T1D
at four years. No relationship between the IA and the standard deviation scores (SDS)-based BMI
is found [80] in the three studies from Germany that used BABYDIAB data [80] and combined
data of BABYDIAB and BABYDIET [9, 84]; however, the ‘two step’-based Cox proportional
hazard modeling [9] is used in an earlier infant SDS-based BMI peak predicting IA. By applying
a model-based clustering technique to derive SDS-based BMI growth patterns which are used to
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predict IA in logistic regression model [84], early BMI growth patterns are associated with IA risk
in children of non-diabetic mothers only. However, no association is found between BMI growth
patterns and IA risk in the whole dataset and in children of diabetic mothers, respectively. In the
Diabetes Prediction in Skåne (DiPiS) study [26] the linear association of SDS-based BMI growth
with T1D development in children during the first 18 months of life was not found using ANOVA
analysis.
In TEDDY [32], Cox modeling with time-dependent covariate is conducted and find that greater
weight z-score in the early childhood from birth to age of 4, but not height z-score, predicts a small
increase in the risk of IA, but no association is found between weight or height z-score and T1D.
A longer follow-up of the cohort and evaluation of additional factors is required to identify the
relevance of these findings for determining the risk of diabetes. Nevertheless, no results of height
and weight to predict T1D risk are reported. The different statistical techniques and modeling
analysis methods may cause the inconsistent findings from these studies, multivariate longitudinal
biomarkers, different genetic, environmental factors of first degree relatives (FDR) and followingup at different age periods. Thus, the 723 pediatric patients with recorded height and weight and
at least three measurements of these two markers are the data for our analysis. Time-to-event
data in the T1D study for each patient is also recorded; event time is collected at the year level,
which is referred to as right-censored event times. Table 1 indicates the descriptive statistics of the
motivating dataset. This study includes 723 participants, 246 (33.61%) participants diagnosis of
T1D during the study period, 399 (54.50%) subjects are male, the mean of the baseline height and
weight are 50.91 (cm) and 3.56 (kg), respectively.
Certain inherent data features exist in this dataset, make the complicated longitudinal data from
ideal. First, two longitudinal exposures (height and weight) are involved in this study and they are
highly correlated as presented in Figure 1(A) the traditional joint modeling has been made in the
univariate data framework [48], ignoring the correlation between the longitudinal exposures can
lead to potential bias. Second, Figure 1(B) and (C) present the histogram of repeated measurements
of height and weight, respectively. Height and weight growth measurements are often skewed as
represented in Figure 1(B) and (C); Due to the computational convenience, majority of the statisti-
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Table 1 Descriptive statistics for variables measured for T1D dataset (N=732). Proportion for
categorical variables and mean (SD) for quantitative variables.
Variables
Number of Patients
Gender
Male
Female
Nation
Germany
Sweden
Finland
US
HLADR34
Yes
No
FDR
Yes
No
Baseline Value
Height(SD⇤ )
Weight(SD⇤ )
⇤: Standard deviation.

A

Total
732

T1D Patients
246(33.61%)

Censored Patients
486(66.39%)

399(54.50%)
333(45.50%)

24(52.03%)
118(47.97 %)

30( 55.76%)
215(44.24%)

54(7.40%)
252(34.40%)
189(25.80%)
234(32.40%)

24(9.76%)
74(30.08%)
76(30.89%)
72(26.27%)

30(6.17%)
178(36.63%)
113(23.25%)
165(33.95%)

359(49%)
373(51%)

134(54.47 %)
112(45.53%)

225( 46.30%)
261(53.70%)

139(54.50%)
593(45.50%)

62(25.20%)
184(74.80%)

77(15.84%)
409(84.16%)

50.91(2.46)
3.56(0.51)

50.89(2.56)
3.57(0.50)

50.92(2.42)
3.55(0.52)

B

C
0.015
0.05

60

0.04

0.010
40

density

density

weight_kg

0.03

0.02
0.005

20

0.01

0
0.000
60

90

120

height_cm

150

0.00
60

90

120

height_cm

150

0

20

40

60

weight_kg

Figure 1. Correlation between repeated measurements of height and weight (A). Histogram of
repeated measurements of height and weight, respectively (B-C).

10

cal approaches assume that the model errors follow normal distribution [81, 60, 82, 85]. Although
the applications are still dominated the findings from these models, it is widely accepted that lack
the robustness and misleading results can be produced by the misspecified normal assumption
[44, 46]. Therefore, we have to consider these data features, and it motivates us to develop the
MVJM approach with SN distribution.
2.2

Primary biliary cirrhosis study

Our second motivating dataset comes from the research on primary biliary cirrhosis (PBC) study
from Mayo clinic [62] . PBC, recently known as primary biliary cholangitis, is a relatively rare
disease caused by inflammatory destruction of the small bile ducts from the liver. Eventually, this
pressure build-up will harm the bile ducts leading to liver cell damage and cirrhosis. The cause
of PBC is unknown, but because the body’s immune system attacks its own cells, it is most likely
thought to be an autoimmune disease. In this disease, the bile ducts are under attack and are
destroyed [31]. Women are more likely than men to have PBC; it is most often in the woman
above the age of 40 [54, 72].
This dataset is from Mayo Clinic trial in PBC of the liver conducted between 1974 to 1984 [29,
62]. The data were collected to examine the progress of PBC patients. A total of 424 PBC patients
met the eligibility criteria for the randomized placebo-controlled trial of the drug D-penicillamine,
referred to Mayo Clinic during that ten-year interval. This dataset contained multiple laboratory
results, but only the first 312 patients in the dataset participated in the randomized trial and obtained
large complete data. The additional 112 cases did not participate in the clinical trial but consented
to have basic measurements recorded and to be followed for survival.
The dataset collected clinical, demographic and biochemical risk factors for each patient. Demographic factors: age and sex of patients; biochemical factors: drug (D-penicillin and placebo
group), ascites (accumulation of water in the abdomen due to liver failure, presence of ascites
0 = No, 1 = Yes), hepatomegaly (liver growth status, presence of hepatomegaly 0 = No, 1 = Yes),
edema (presence of edema, 0=No, 1=Yes: edema present without diuretics or edema despite diuretic therapy) and histological stage(

3 is yes). SB (mg/dl), SA (mg/dl) and SGOT (U/ml)
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values were taken as biochemical properties. Sample sizes and descriptive statistics for key variables at study entry were shown in Table 3. Only the patients who had three or more measurements
of all the biomarkers were considered in the analysis due to the feature of our longitudinal modeling (quadratic of the year was included). Thus, 259 patients who had sufficient repeated biomarkers observations were included in the analysis, where 111(42.9%) died during the study. Table 2
summarized the demographic characteristics of patients who died and were censored. Of the 259
patients in the PBC dataset, the mean age at baseline of this PBC dataset was 45.53 ± 10.42 years,
and the mean age of death for PBC patients was 52.50±10.30 years. Baseline value of natural loga-

rithms of SB, SA and SGOT were 0.47±0.95(mg/dl), 1.21±0.16(mg/dl) and 4.70±0.45(U/ml),
respectively.
In the PBC study, it is of interest to use repeated measurements of patient-specific blood test
biomarkers (different serum levels) to help predict the occurrence of patient-specific events (e.g.,
death, transplantation). Previous studies [1, 3, 20, 21, 40, 22, 24, 67] have used joint modeling
to explore this association by modeling the association between the patient-specific longitudinal
trajectory for serum bilirubin and the survival event endpoint (death). However, this approach
ignores the dependence among different serum biomarkers serum bilirubin (SB), serum albumin
(SA) and serum Glutamic-Oxaloacetic transaminase (SGOT) taken on the same patient. Arguably,
a more appropriate analysis approach would model the correlation among measurements taken on
a person’s different serum exposures. Hence, consider a joint modeling approach in which we
could then explore the association between the longitudinal trajectories for (SB, SA and SGOT)
and a patient-specific endpoint for the time to death.
Additionally, all these three biomarkers (SB, SA and SGOT) have taken natural log transformation and they are highly correlated as presented in Figure 2(A) the correlation matrix plot. The traditional JM has been made in the univariate data framework [48], ignoring the correlation between
the longitudinal exposures can lead to potential bias. Figure 2(B) to (D) presents the histograms of
repeated measurements of SB, SA and SGOT levels, respectively. The SB measurements are still
highly skewed as represented in Figure 2(B). Due to the computational convenience, the majority
of the statistical approaches assume that the model error follow normal distribution [81, 60, 82, 85].
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Therefore, we have to pay attention to present an accessible introduction in the epidemiological
and medical literature; it motivates us to demonstrate the MVJM approach application study.
Table 2 Descriptive statistics for variables measured for PBC dataset (N=259). Proportion for
categorical variables and mean (SD) for quantitative variables.
Variables
Number of Patients
Gender
Female
Male
Edema
Yes
No
Histologic 3
Yes
No
Ascites
Yes
No
Hepatomegaly
Yes
No
Baseline Value
Age(SD⇤ )
ln(SB)(SD⇤ )
ln(SA)(SD⇤ )
ln(SGOT)(SD⇤ )
⇤: Standard deviation.

Total
259

Death Patients
111

Censored Patients
148

228(88.03%)
31(11.97%)

89(80.18%)
22(19.82%)

139( 93.92%)
9(6.08%)

41(15.83%)
218(84.7%)

25(22.52%)
86(77.48%)

26(10.81%)
132(89.19%)

186(71.81%)
73(18.19%)

90(81.08%)
21(18.92 %)

96(64.86%)
52( 35.14%)

10(3.86%)
249(96.14%)

9(8.11%)
102(91.89%)

1(0.68%)
147(99.32%)

125(48.26%)
134(51.73%)

73(65.77%)
38(34.23 %)

52(53.14%)
96( 64.86%)

49.53(10.42)
0.58(1.09)
1.26(0.11)
4.70(0.446)

52.50(10.30)
0.93(1.01)
1.24(0.13)
4.83(0.45)

47.30(9.99)
0.12(0.74)
1.28(0.09)
4.61(0.42)
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Figure 2. Correlation matrix plot of transformed repeated measurements of three serum levels.
Histogram for Bilirubin, Albumin and SGOT, respectively (B-D).
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Chapter 3
Bayesian joint modeling for multivariate longitudinal and time-to-event data

3.1

Introduction

In epidemiologic and clinical studies, much attention is focused on developing the specific patterns
of the longitudinal measurements and the associations between these patterns and the time to a
certain event, such as to diagnose of disease, time to transplantation or death. These studies have
been in a highly active research area [10, 37, 66, 69, 79]. For example, in type 1 diabetes studies,
repeated measures of continuous exposures such as the time to type 1 diabetes (T1D) and children’s
growth (height and weight) are collected.
During the last two decades, the research on joint modeling of longitudinal and time-to-event
data has been received rapid and considerable development. Such event time and longitudinal
observations are prevalent in many scientific fields such as in biomedical, biology and clinical research where statistical analyses are adopted. As a consequence, a substantial number of statistical
approaches and analysis methods have been suggested for analyzing such longitudinal and time-toevent data. The following issues may stand out. (i) Most joint models focus on a single longitudinal
variable associated with a survival outcome [10, 37, 66, 69, 79]. However, in practice, many studies are often to collect multiple longitudinal outcomes [1, 11, 14, 15, 28, 50, 59, 63, 64, 70, 76, 77]
which may be significantly correlated. For example, the weight and height repeated measures presented in Figure 3 (left and middle panels) are significantly correlated; it may reduce efficiency
and lead to bias in estimation if ignoring their correlation; moreover, time-to-event outcome such
as the time to diagnosis type 1 diabetes (T1D) depicted in Figure 3 (right panel) may be dependent
on the longitudinal weight and height measures. (ii) In traditional linear mixed-effects models, the
model errors are often under a normality assumption due to the computational convenience and
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mathematical tractability. However, the normality assumption may not be realistic. Alternatively,
the skew-elliptical (SE) distributions, including skew-normal (SN) distribution (see Appendix A in
detail), should be more appropriate to model the skewed data [71]. Although a few studies investigated multivariate joint modeling (MVJM) [1, 14, 15, 50, 70, 77, 76], they have not considered
non-normal feature of longitudinal data.

Profiles of Weight versus age

K−M survival curve for T1D
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Figure 3. Randomly selected 50 trajectories of weight (left panel) and height (middle panel) from
diabetes study. Kaplan-Meier survival plot (right panel) for T1D.
Most of the statistical researches have focused on the development of models that aim to capture only one particular aspects of the motivating study for modeling of longitudinal data. When
multiple longitudinal outcomes data with correlation and skewed distributions are considered in
conjunction with time-to-event into MVJM, the inferential approaches can be complicated dramatically. Our Bayesian approach enables the fitting of such models efficiently and the convergence
problem can be solved.
To the best of our knowledge, only few works has been considered on modeling longitudinalsurvival data via MVJM and simultaneously accounting for skewness. A Bayesian inferential
analysis is applied to estimate the parameters of the joint modeling. The rest of the chapter is
organized as follows: (i) we introduce MVJM with the SN distribution and discuss the associated
Bayesian inferential method; (ii) we present the dataset from a diabetes study that motivated this
research, apply the proposed MVJM to the data and report the results; (iii) conducts limited sim-
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ulation studies to evaluate the performance of the proposed models and method; Finally, general
discussion and conclusion are presented.
3.2

Joint modeling and associated Bayesian approach

In this section, we describe the MVJM and associated Bayesian modeling method in full generality
for multivariate longitudinal data with skew-normal and correlation, and discrete time-to-event
endpoints with censoring, to illustrate that our methodology is able to be implemented in different
applications. We assume the multivariate longitudinal model with skew-normal (SN) distribution,
in order to make a more robust inference and loosen the normality assumption. Let yijk be a
measure of the k th longitudinal variable (k = 1, 2, . . . , K) from the ith subject (i = 1, 2, . . . , n)
at time tijk of visit j (j = 1, 2, . . . , ni ). Let Y i = (Y Ti1 , . . . , Y TiK )T be the K-variate vector
of continuous longitudinal responses, where Y ik = (yi1k , . . . , yini k )T . Similarly, we can define
X i and Z i . Denote the vector of population parameters by
(

0k ,

1k ,

2k , . . . ,

pk )

T

= (

†T
1 ,...,

†T T
K )

†T
k

with

=

related to the k th longitudinal variable. The vector of subject-specific

parameters by bi = (bTi1 , . . . , bTiK )T with bTik = (bi0k , bi1k , bi2k , . . . , biqk )T . In a clinical research
study, several types of events may occur to a subject. Denote Ti⇤ as the ‘failure’ time, Ci as the
censoring time and Ti = min(Ti⇤ , Ci ) as the observed time for ith subject. Let ⇢ij be the indicator
for an event, that is, ⇢ij = 1 (Ti⇤  Ci ) when the event is observed and ⇢ij = 0 when censoring
occurs. xi is a vector of covariates which may be associated with a time-to-event.
3.2.1

Multivariate linear mixed-effects models with SN distribution

We consider a general multivariate linear mixed-effects model with SN distribution as follows.
Y ik = X ik

k

+ Z ik bik + ✏ik ,
iid

(3.1)
bi = (bTi1 , . . . , bTiK )T ⇠ NKq (0, ⌃b ),
⇣ p
⌘
iid
✏i = (✏Ti1 , . . . , ✏TiK )T ⇠ SNKni
2/⇡[ K ⌦ 1ni ], ⌃K ⌦ I ni , K ⌦ I ni ,
where the vector of random errors ✏i follows a multivariate SN distribution with unknown
variance-covariance matrix ⌃K = (
eter matrix

K

= diag( 1 , . . . ,

K ),

2
kk0 )K⇥K

(k, k 0 = 1, 2, . . . , K), unknown skewness param-

the vector of skewness parameters
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K

= ( 1, . . . ,

K)

T

, and

1ni = (1, . . . , 1)T . Note that

p
2/⇡[

K

⌦ 1ni ] is specified here to make the SN distribution

with mean zero; see Chapter 1 for detailed discussion of SN distribution. bi is a vector of randomeffects which follows NKq (0, ⌃b ) with ⌃b being a covariance matrix. In the application below,
we are interested in the height and weight longitudinal data. Let

2

= diag( 1 , 2 ), and

1

and

2

quantify skewness of height and weight, respectively, which is the case represented in this article.
3.2.2

Cox proportional hazard model

In survival analysis, the semiparametric Cox proportional hazard model[19] has been commonly
used to investigate the association between survival time and one or more covariate in medical
research. To explain the association between the multiple longitudinal outcomes, we assume that
the distribution of Ti , which is the time to diagnosis of T1D for the ith subject, depends on the
random-effects of individual-specific longitudinal processes bik , and other risk covariates xi , respectively. The survival model appraised for Ti is linked with the multivariate longitudinal model
(3.1) via the random-effects bi . The other baseline covariates xi are also assumed to be connected
with the event time. Specifically, for the survival-sub model, the conditional hazard rate of Ti at
time ti is represented as
(ti |bi , xi ) =
where

0 (ti )

0 (ti ) exp(⌥

T

b i + ↵ T xi ) =

0 (ti ) exp(

is the baseline hazard function, di = (bTi , xTi )T ,

T

(3.2)

di ),

= (⌥T , ↵T )T , ⌥ and ↵ are

the unknown parameters linked through the random-effects bi and covariates xi to the conditional
hazard rate, respectively.
Let ⇢i = (⇢i1 , . . . , ⇢ini )T be a vector of censoring indicator for individual i: ⇢ij = 1 if the
participant get T1D by time tij ; otherwise, ⇢ij = 0. We assume that ⇢i1 = 0 for all individuals.
In the real data application, let Ti be the time to T1D and assume P (Ti < 1) = 1 for individual
i, but it is not accurately recorded due to the study design. Interval censored event time is called

for this type of time-to-event data structure. Specifically, if T1D of individual i is recorded at
time tij , it means that the T1D time Ti takes place between the time intervals (ti,(j
ti,(j

1)

< Ti  tij . Also, we take ⇢i1 = . . . = ⇢i,(j

1)

that is,

= 0 and ⇢ij = . . . = ⇢ini = 1. If no such

event has happened, we treat ⇢ij = 0 for j = 1, . . . , ni , and thus Ti > tini .
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1) , tij ],

From equation (3.2), the probability of time-to-event is given as
pij = P (⇢ij = 1|⇢ij ⇤ = 0, 0  j ⇤ < j) = 1 P (Ti tij |Ti > ti(j 1) )
!
Z tij
P (Ti tij )
T
=1
= 1 exp
di )
0 (t)dt exp(
P (Ti ti(j 1) )
ti(j 1)
where

0j

(3.3)

= 1 exp( exp( 0j + T di )),
⇣R
⌘
tij
= log ti(j
(t)dt
, j = 1, . . . , ni . Comparison to the parameter estimation0
1)

based method, under the current observation system, only the finite number of parameters
required to grip, instead of the unknown baseline hazard function

0 (t).

0j

are

The contribution to the

likelihood from the time-to-event model for the ith subject is denoted by f (⇢i |di ). Thus, we have
Q i
(3.4)
f (⇢i |di ) = nj=1
f (⇢ij |⇢ij ⇤ , 0  j ⇤ < j; di ),
⇢

where f (⇢ij |⇢ij ⇤ , 0  j ⇤ < j; di ) = pijij (1

pij )1

⇢ij

and ⇢ij equals to 0 before death and 1

after death. Let ◆i = max(tij : ⇢ij = 0) and uij = min(tij : ⇢ij = 1). With (3.4), the following
probability of time-to-death can be expressed as
✓ Z ◆i
◆
T
P (◆i < Ti  ui |di ) =exp
di )
0 (t)dt exp(
0

✓ Z ui
· 1 exp
0 (t)dt exp(
◆i

T

di )

◆

(3.5)
,

where ui = 1 if ⇢ij = 0 for j = 1, . . . , ni . The procedure we deliberated above is an alternative

method to approximate the Cox proportional hazard model through the counting process [17]. It
can diminish some computing load and clarify the presentation.
3.3

Simultaneous Bayesian inferential approach

Generally, different approaches are applied to link the longitudinal and survival submodels. The
likelihood inferential methods are considered as the statistical approach, such as Monte Carlo
Expectation-Maximization (MCEM) algorithm and Expectation-Maximization (EM) algorithm
[27, 65]. A simultaneous inference approach reached from a joint likelihood may be favorable,
but the computational burden for proposed MVJM can be immensely intensive, even sometimes
infeasible, and could have convergence problems [10, 82]. The second approach is Bayesian inference; the Bayesian joint modeling method shows the advantage. Consequently, we estimate all

19

the parameters for the MVJM simultaneously under the umbrella of a fully Bayesian methodology using Markov Chain Monte Carlo (MCMC) techniques for the skew-normal multivariate joint
model. The simultaneous statistical inference on all unknown model parameters can capture the
underlying association between the longitudinal responses and the time-to-event data.
First, bik and ✏ik are assumed mutually independent of each other. In order to specify the model
(3.1) for MCMC computation, it can be shown by introducing the ni -dimensional random vector
wi based on the stochastic representation of SN distribution described in Chapter 1 of the publication [87], we hierarchically formulate the MVJM, which consists multivariate linear mixed effect
model (3.1) and Cox proportional hazard model (3.2) as follows.
⇣
⌘
p
Y i |bi , wi ⇠ N X i + Z i bi + K ⌦ [wi
2/⇡1ni ], ⌃K ⌦ I ni ,
wi ⇠ Ni (0, I ni )I(wi > 0), bi ⇠ NKq (0, ⌃b ) ,
R
Ti ⇠ F (ti |di , 0 ) = f (⇢i |bi , xi ),

(3.6)

The simultaneous statistical inference on all unknown population parame- Then, under the
umbrella of Bayesian inference, we need to specify all unknown population parameters ✓ =
( , , ⌃b , ⌃K ,

K)

ness parameters is

as the collection in the joint model (3.1) and (3.2), where the vector of skewK

= ( 1, . . . ,

K)

T

. We assign weakly informative priors to ensure the property

of posteriors. Thus, we specify prior distributions for all of the unknown parameters as follows:
⇠N(

0 , ⌦1 ) ,

⌃K ⇠ IW (⌦4 , !2 ),

⇠ N(
K

0 , ⌦2 ),

⌃b ⇠ IW (⌦3 , !1 ),

⇠ N (0, ⌦5 ),

(3.7)

where the mutually independent Normal (N ) and Inverse Wishart (IW ) prior distributions are
chosen to facilitate computations. The super-parameter matrices ⌦1 , ⌦2 , ⌦3 , ⌦4 and ⌦5 can be
assumed to be diagonal for convenient implementation.
Subsequently, let f (·), f (·|·), F (·|·) and ⇡(·) denote a density function, a conditional density
function, a cumulative density function (c.d.f) and a prior density function, respectively. As the
elements of ✓ = { , , ⌃b , ⌃K ,
⇡( )⇡( )⇡(⌃b )⇡(⌃K )⇡(

K ).

K}

are assumed to be independent of each other, we have ⇡(✓) =

After we specifying the MVJM for the prior distributions and the

observed data for the unknown parameters, we can apply the Bayesian inference for the parameters
estimation according to the posterior distributions. Thus, the joint posterior density of ✓ based on
the observed data D = {Y i , bi , ⇢i } can be represented by
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n Z
Y
f (✓|D) / {
f (Y i |bi , wi )f (bi )f (wi |wi > 0)f (⇢i |bi , xi )dbi }⇡(✓).

(3.8)

i=1

In general, the integrals in (3.8) are high dimensional and do not have a closed form. Since analytic approximations to the integrals may not be sufficiently accurate, it is prohibitive to directly
calculate the posterior distribution of ✓ based on the observed data. Alternatively, the MCMC
procedure can be used to sample population parameters ✓, and random-effects bi from conditional
posterior distributions based on (3.8), by employing the Gibbs sampler along with the MetropolisHastings (M-H) algorithm. This process is repeated in iterations of MCMC procedure until convergence is reached by using the public and freely available WinBUGS software [61] interacted
with a function called bugs in a package named R2WinBUGS of R. One advantage of using the
WinBUGS software is that it is not necessary to explicitly specify the full conditional posterior
distributions for parameters to be estimated. Although their derivations are straightforward based
on the complete joint posterior (3.8), due to some cumbersome algebra, they are not presented here
to save space.

3.4
3.4.1

Application
Motivating dataset

In Chapter 2, section 2.1 has briefly described the pediatric T1D dataset that motivated this research. This study recruited the children who were screened for genetic predisposition for T1Drelated Human Leukocyte Antigen-antigen D and isotype R (HLA-DR) genotypes when they were
eligible at the time from birth; and both the general population and the first-degree relative (FDR)
are included. The details about the characteristics of families of the diabetes cohort have been reported [8, 58]. It was a prospective study, the pediatric participants participated were followed from
birth to 15 years old in the study, with study visits starting at 3 months of age, then every 3 months
until age of four, and every 6 months after that depending on the development of T1D. The details
of screening procedure and follow-up have been published previously [34, 51]. Data recorded at
each study visit include repeated weight and height measurements, time-to-event outcomes such
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as the first sign of islet autoimmunity (IA) and clinical diagnosis of T1D, biological data, dietary
records, demographic and health histories for the children, and psychological measurements [33].
In our application here, we used the dataset of 732 children from all subjects who had developed to IA which is the preclinical sign for potentially clinical diagnosis of T1D and had weight
and height measurements repeatedly from birth to age at diagnosis of T1D or most recent visit.
The confirmed T1D was defined as confirmed positive antibodies to insulin, glutamic acid decarboxylase, or insulinoma antigen 2, which were analyzed by radiobinding assays on at least 2
consecutive study visits [56]. For children with an event occurred, only repeated measurements up
to the date of diagnosis of T1D were included in the analysis, while for subjects with censoring,
repeated measurements up to the age 15 were used. In studying the pathogenesis of autoimmune
T1D, it was tested if growth was affected prior either to the first sign of IA or to clinical diagnosis
of T1D in children with IA [56]. A child’s growth trajectory in early life shows a quadratic pattern
approximately as displayed in Figure 3 (left and middle panels). An individual’s pattern may be
an essential clinical indication, since it might be connected with the risk for the clinical diagnosis
of T1D. The Kaplan-Meier (K-M) survival curve for T1D as the event was displayed in Figure 3
(right panel). Among the 732 children, 246 (33.61%) subjects were progressed to T1D. In the
survival sub-model, these main covariates used including gender (female vs. male), country of
residence (Finland, Germany, Sweden as compared to U.S.), HLA genotype (HLA-DR3/4 genotype compared with others) and first-degree relatives (FDR) status (yes or no) which are the most
genetic factors and critical environmental in this diabetes cohort study.

3.4.2

Model implementation

We illustrate our models and method of the part of longitudinal data described in Section 3.1.
We used an SN multivariate linear mixed-effects model with random intercept, random slope and
quadric of age and gender for the longitudinal submodel and adjusted for random intercept and
random slope, gender, HLA genotype and FDR status at baseline in the survival submodel. We
consider the following specific bivariate linear mixed-effects models for height and weight:
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yijk = (

0k

+ bi0k ) + (

1k

+ bi1k )Ageij +

2
2k Ageij

+

3k Genderi

+ eijk ,

(3.9)

for k = 1, 2 ,
Specifically, where k = 1 and k = 2 correspond to the height and weight responses, respectively.

yij1 and yij2 are the respective standardized height and weight observations for the ith subject
at time tij ; the random-effects bi0k and bi1k represents a random intercept and a random slope,
respectively. This model assumes that the mean baseline measurement (intercept), mean rate of
change (slope) and quadratic of age are different between male and female.
The survival analysis of the joint modeling is explained in section 2.3. The Cox proportional
hazard model applied in our study is specific as:
(ti |bi , xi ) =

0 (ti )exp( 1 bi01

+

2 bi11

+

3 bi02

+

4 bi12

+ ↵1 Finlandi +

↵2 Germanyi + ↵3 Swedeni + ↵4 Genderi + ↵5 HLAi + ↵6 FDRi ).
where ⌥ = ( 1 ,

2,

3,

4)

T

(3.10)

is the parameters corresponding to the random-effects bi =

(bi01 , bi11 , bi02 , bi12 ) and other risk factors are included in the survival sub-model. ↵ = (↵1 , . . . , ↵6 )
is corresponding to the risk factors include country of residence (Finland, Germany, Sweden), gender (female=1), HLA genotype and FDR status.
In the diabetes study data, since height and weight, these two outcome variables exhibit skewness and outliers. Follow with the nature of the diabetes study, the model N and model SN with
specifying different distributions are implemented to compare their performance as follows:
• Model N: MVJM with the N distribution for the model errors.
• Model SN: MVJM with the SN distribution for the model errors.
When the skewness parameter is zero, a normal distribution is a particular case of an SN distribution. Using a symmetric normal distribution contributes to modeling results and parameter
estimation in comparison with that using an asymmetric SN distribution to explore the MVJM
approach.
To perform the Bayesian inference process, we have to specify the values for the hyperparameters in the prior distributions (3.7). Due to the absence of historical data, we apply weakly
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informative prior distributions for the parameters in MVJM. In particular, (i) each element of the
population parameter vectors ,

and ↵ is taken to be independent normal distribution N (0, 100);

(ii) the priors for the variance covariance matrices ⌃K and ⌃b are taken to be inverse Wishart
distributions IW (diag(0.01, 0.01), 3) and IW (diag(0.01, 0.01, 0.01, 0.01), 5); (iii)for each of the
skewness parameter

1

and

2,

which represent the skewness of height and weight, respectively,

independent normal distribution N (0, 100) is chosen.
The MCMC sampler is implemented by WinBUGS software [61] interacted with R2WinBUGS
form R software, Appendix A is the program code. When the MCMC procedure is applied to
the diabetes study data, the convergence of the generated samples is assessed using standard tools
within WinBUGS software such as trace plots and Gelman-Rubin (GR) diagnostics [30]. Figure
4 shows the trace plots and dynamic version of GR diagnostic plots based on Model SN for the
representative parameters

01 ,

02 ,

1,

4,

↵1 and ↵6 . We inspect from trace plots (left panel) that

the three different curves mix or cross in the trace, indicating that convergence is reached. For
the plots of GR diagnostics (right panel) where the three curves are given: the middle and bottom
curves below the dashed horizontal line (indicated by the value 1) represent the pooled posterior
variance (V̂ ) and average within-sample variance (Ŵ ), respectively; and the top curve represents
their ratio (R̂). It is seen that R̂ is generally expected to be higher than one at the initial stage
of the algorithms, but R̂ tends to 1, and V̂ and Ŵ stabilize as the number of iterations increases,
indicating that the algorithm has approached convergence.
When these criteria suggested the convergence of chains, we proposed that, after an initial number of 10,000 burn-in iterations of three chains of iterations of 30,000, every 20th MCMC sample
was retained from the next 10,000 for each chain. Thus, we can totally get 3,000 samples of
targeted posterior distributions of the unknown parameters for statistical inference. Even though
this is a high-dimensional computation working load, the MCMC algorithm conducting by the
WinBUGS program will have no trouble regarding the convergence of a solution for the inverse
of matrices and parameter estimates in this application. The results based on the two scenarios
highlighted above are reported in the following section.

24

beta01 chains 3:1

beta01 chains 1:3

64.2
64.0
63.8
63.6
63.4
63.2

2.0
1.5
1.0
0.5
0.0
1350

1400

1450

551

iteration

800
iteration

beta02 chains 3:1

beta02 chains 1:3

8.0

2.0
1.5
1.0
0.5
0.0

7.8
7.6
7.4
1350

1400

1450

551

iteration

800
iteration

delta1 chains 3:1

delta1 chains 1:3

-4.5
-4.6
-4.7
-4.8
-4.9

1.5
1.0
0.5
1350

1400

1450

551

iteration

800
iteration

upsilon4 chains 3:1

upsilon4 chains 1:3

1.0

1.5

0.5

1.0

0.0

0.5

-0.5

0.0
1350

1400

1450

551

iteration

800
iteration

alpha1 chains 3:1

alpha1 chains 1:3

1.5
1.0
0.5
0.0
-0.5

1.2
1.1
1.0
0.9
0.8
1350

1400

1450

551

iteration

800
iteration

alpha6 chains 3:1

alpha6 chains 1:3

1.0

1.5
1.25
1.0
0.75
0.5

0.5
0.0
-0.5
1350

1400

1450

551

iteration

800
iteration

Figure 4. Convergence diagnostics with three Markov chains as obtained from the WinBUGS software for representative parameters based on Model SN: trace plots (left panel); Gelman-Rubin
(GR) diagnostic plots (right panel), where the middle and bottom curves below the dashed horizontal line (indicated by the value one) represent the pooled posterior variance (V̂ ) and average
within-sample variance (Ŵ ), respectively, and the top curve above the dashed horizontal line represents their ratio (R̂).
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3.4.3

Data analysis results

Bayesian joint modeling method based on multivariate linear mixed effect models to fit height and
weight, as well as time-to-event data jointly is proposed. From the model fitting results, we have
seen that, in general, longitudinal sub-model provides a rationally good fit to the observed data for
majority participants in the study; in particular, the three selected individual estimates of the height
and weight trajectories obtained by applying the MVJM approach based on Models N and SN are
depicted in Figure 5. We can see that the estimated individual trajectories for Model SN where the
measurement error is assumed to be skewness normal fit the observed data more closely than these
for Model N where the measurement error is assumed to be normally distributed. The following
findings are obtained from MVJM results. The estimated individual trajectories for Model SN fit
the initially observed values more closely than these for Model N.
To access the goodness-of-fit of the two models based on the MVJM approach, the diagnose
plot of observed value versus fitted values of height and weight based on Models N and SN are
represented in Figure 6. It is shown from Figure 6 that Model SN provides a much better fit to the
observed values of height and weight, as compared to Model N.
Table 3 presents the population posterior mean (PM), the corresponding standard deviation and
95% equal-tail credible interval (CI) for the fixed-effects parameters and Cox proportional hazard
model parameters based on Models SN and N. From the results of estimated parameters, we get
the following findings. Firstly, in the multivariate longitudinal model (3.9), the results present
that these estimates are different from zero since 95% CIs do not contain zero. In particular,
for the parameters that are of interest, the estimates of

11

and

12

for the growth rate of height

and weight, respectively, for Model SN are slightly smaller than their counterparts for Model N,
while the baseline estimates of

01

and

02

from Model SN are slightly larger than these from

Model N. Secondly, the estimates of the within-subject variances

2
11 ,

2
22

and covariance

2
12

for Model SN are smaller than their counterparts for Model N. This is expected because of high
variability, heaviness of the tails and skewness are pertinent to a certain criteria. The estimates
of the skewness parameters

1

=

4.68 and

2

=

1.82 are significant negative for Model SN.

The results provide evidence that obvious left-skewness exists in our data. Consequently, Model
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Figure 5. The individual estimates of height and weight trajectories for 3 randomly selected patients
based on the two models (Model N: dashed line; Model SN: dotted line). The observed values are
indicated by circles.
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SN containing the skewness parameters is recommended. Thirdly, there is an interesting finding in
the Cox proportional hazard model (3.10) for the time-to-event process. Model SN indicates that
the estimated association of two parameters of the height and one parameter of weight
95% CI ( 0.33

0.27 with

0.21), 0.95 with 95% CI (0.69, 1.22) and 0.42 with 95% CI 0.42(0.25, 0.62) are

significantly associated with the risk of T1D. In the comparison of Model SN and Model N, there
are not too many differences for the parameter estimates of the Cox proportional hazard model.
The estimated results also show that it is not directly associated with the covariates of Sweden and
gender because of the insignificant estimates of ↵3 and ↵4 .
To further select the best model that fits the data adequately, a Bayesian selection criterion,
known as deviance information criterion (DIC) [74], is adopted. With caution here, DIC, which
is not intended to identify the “correct” model, is only used to find the one that fits the data best.
In order to compare models under different settings, the DIC values obtained are also summarized
in Table 3. It is seen that the DIC value in Model SN is smaller than its counterpart in Model N,
suggesting that Model SN produces a better fit than Model N in terms of DIC value. Thus, we
further report the findings based on Model SN in detail.

A
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Figure 7. Hazard ratio (HR) in survival sub-model based on Model SN; effects of association
parameters (left panle) and baseline covariates (right panel) in risk of T1D
The estimated results based on Model SN in Table 3 indicate the skewness parameters in
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Table 3 Summary of estimated posterior mean (PM) of population (fixed-effects) parameters and
Cox proportional hazard model parameters, the corresponding standard deviation (SD) and 95%
equal-tail credible interval (CI) as well as DIC values.
Parameter
PM

01
11
21
31
02
12
22
32
1
2
2
11
2
12
2
22

1
2
3
4

↵1
↵2
↵3
↵4
↵5
↵6
DIC

63.63
11.69
-0.37
-1.55
7.67
2.13
0.079
-0.58
-4.68
-1.82
1.21
-0.44
0.74
-0.27
0.95
0.42
0.32
0.51
0.58
-0.15
-0.054
0.34
0.43

Model SN
SD
95%CI

PM

Model N
SD
95%CI

Multivariate longitudinal parameter estimates
0.13 (63.38, 63.88)
61.89 0.12 (61.66, 62.15)
0.05
(11.6, 11.8)
12.74 0.04 (12.66, 12.81)
0.01 (-0.38, -0.36)
-0.467 0.01 (-0.473, -0.461)
0.21 (-1.96, -1.15)
-1.52 0.17 (-1.87, -1.18)
0.07 (7.53, 7.79)
7.01
0.06
(6.89, 7.13)
0.03 (2.07, 2.19)
2.53
0.06
(2.47, 2.59)
0.01 (0.077, 0.082)
0.044 0.01 (0.041, 0.046)
0.09 (-0.76, -0.40)
-0.57 0.08 (-0.73, -0.41)
0.03 (-4.75, -4.61)
–
–
–
0.03 (-1.86, -1.77)
–
–
–
0.05 (1.12, 1.33)
9.99
0.11
(9.78, 10.21)
0.02 (-0.48, -0.39)
2.96
0.04
(2.87, 3.04)
0.02 (0.74, 0.79)
2.06
0.02
(2.01, 2.10)
Survival parameter estimates
0.03 (-0.33, -0.21)
-0.35 0.04 (-0.43, -0.27)
0.13 (0.69, 1.22)
1.26
0.18
(0.94, 1.67)
0.09 (0.25, 0.62)
0.43
0.09
(0.26, 0.63)
0.17 (-0.027, 0.65)
0.29
0.18
(-0.07, 0.65)
0.17 (0.18, 0.84)
0.41
0.18
(0.04, 0.41)
0.26 (0.037, 1.08)
0.51
0.18
(0.01, 0.52)
0.18 (-0.51, 0.19)
-0.34 0.18
(-0.70, 0.03)
0.14 (-0.33, 0.21)
-0.03 0.14
(-0.31, 0.25)
0.14 (0.061, 0.62)
0.38
0.14
(0.09, 0.66)
0.17 (0.076, 0.76)
0.45
0.18
(0.10, 0.79)
122274
160068
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height ( 4.68) and weight ( 1.82) are estimated to be significantly negative. This indicates
the skewness with the heavy left tail of height and fairly left tail of weight. Thus, it may suggest that accounting for a multivariate linear mixed-effects joint modeling with the SN distribution
provides a better fit to the data, which exhibit skewness and, in turn, gives more reliable estimates of the parameters. The estimated results of fixed-effects presents in Table 3 based on
Model SN indicate that the growth rate of height and weight with covariates quadratic term of
age and gender may be approximated by yˆ1 = 63.63 + 11.69Age

0.37Age2

1.55Gender and

0.58Gender, respectively. The quadratic of age and gender

yˆ2 = 7.67 + 2.13Age + 0.079Age2

are all significant for the longitudinal sub-model of the MVJM. Figure 7 depicts the Hazard ratio (HR) in survival sub-model based on Model SN; effects of association parameters (left panle)
and baseline covariates (right panel) in risk of T1D. Consequently, based on the Cox proportional
sub-model, the results show that the hazard ratio of the estimated association parameter

2

is

exp( 2 ) = 2.59 with 95% CI being (1.99, 3.39) is statistically significant, indicating that a positive association between estimated change rate of height and risk of T1D diagnosis is found after
adjusting for country of residence, gender, HLA genotype and FDR status. We also find that HLA
genotype HR=exp(↵5 ) = 1.40 with 95% CI (1.06, 1.86)) and FDR HR=exp(↵6 ) = 1.54 with 95%
CI (1.08, 2.14)) are significantly associated with higher risk of T1D. However, gender is not found
to be significantly associated with the risk of T1D. Note that this uncompounded approximation
considered here only provides rough guidance and points to further T1D research, since the true
association in medical research may be more complicated.

3.5

Simulation studies

To assess performance of the proposed MVJM method, we conduct the following limited simulation studies. The design of the simulated data is mimic to the diabetes data used in Section 3.
Specifically, we choose the sample size n = 500, and assume that each subject has 32 scheduled
longitudinal measurements. The measurement time points are mimicked these in the real data
analysis, and the true parameter values are selected as follows:
(59, 11, 0.3, 0.1)T ,

†T
2

= (

02 ,

12 ,

22 ,

32 )

T

†T
1

= (

01 ,

11 ,

= (6, 2, 0.5, 0.5)T , ⌥ = ( 1 ,

31

21 ,
2,

3,

31 )

T

=

T

=

4)

( 0.2, 1, 0.4, 0.3)T and ↵ = (↵1 , ↵2 , ↵3 , ↵4 , ↵5 , ↵6 )T = (0.7, 0.8, 0.3, 0.4, 0.3, 0.4)T . Longitudinal data are simulated based on equation (3.9), with each model including subject-specific
random intercepts and slopes with bi = (bi01 , bi11 , bi02 , bi12 )T ⇠ N (0, diag(1, 1, 1, 1)), correlation
is induced between the two longitudinal outcomes by generating the random intercepts and slopes

for each outcome from the multivariate normal distribution; we simulate the model errors ✏ijk under weight response model with (2, 0.8) distribution and height response model with (1, 0.5)
which yield skewed distribution, respectively. To generate the survival data, a constant baseline
hazard of 0.1 is set, and we use an exponential distribution with a mean equal to 0.1 to generate
the censoring time. In Cox proportional regression model, Covariates are simulated depending on
variable types. For example, FDR is simulated from a Bernoulli distribution with p = 0.5, etc. According to the settings described above, because of the intensive computational load, we generate
50 datasets, which are fitted by Models SN and N. Note that the prior distributions considered are
all close to non-informative as similarly treated in real data analysis. Thus, we expect the results
to be somewhat robust with respect to prior distributions.
Table 4 summarizes the simulation results which include the true parameter (TP) values,
percent bias (defined by 100 ⇥ biasl /|TPl |) and percent mean-square-error (MSE) (defined by
p
100 ⇥ M SE l /|TPl |) of fixed-effects , ⌥ and ↵. First, it is of interest to see that the estimated
parameters vary in height and weight for our two longitudinal outcomes, which means extending
the univariate joint model to MVJM allows us to incorporate more information and improves the
efficiency in estimation. Second, in comparison of Models SN and N in the multivariate linear
mixed-effects sub-model, we find that, in general, Model SN performs better than Models N in
terms of smaller MSE and bias. For all the scenarios to be considered in this simulation study,
it is of interest to see that all estimated biases for

21 ,

31

and

these parameters are underestimated, while estimated biases for

22
01 ,

are negative, indicating that
11 ,

12

and

02

are positive,

suggesting that these parameters are overestimated. We note that the larger bias of the growth rate
of height and weight is reasonable, which is inconsistent with the results of the real data analysis.
The average estimates of skewness parameters

1

= 1.44 for height and

2

= 1.57 for weight in

Model SN indicate a departure from (symmetric) normal distribution. Third, for the parameters in
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Table 4 Summary of true parameter (TP) values, estimated parameters, Bias and MSE for Models
SN and N based on 50 simulated datasets. EST is average
p of estimates,pBias and MSE are quantified by percent bias = 100 ⇥ biasl /|TPl | and percent MSE = 100 ⇥ MSEl /|TPl |, respectively.
Model
Parameter

01
11
21
31
02
12
22
32
1
2

1
2
3
4

↵1
↵2
↵3
↵4
↵5
↵6

TP

Model SN
EST
Bias MSE

Model N
EST
Bias MSE

Multivariate longitudinal parameter estimates
59 59.61 1.04
0.64
59.61 1.04 0.64
11 11.81 7.37
6.21
11.85 7.74 0.60
-0.3 -0.30 -1.56 -0.01
-0.30 -1.60 0.01
0.1 -0.10 -1.32 0.01
0.09 -1.16 0.01
6
6.81
13.52 11.21
6.80 13.41 10.84
2
2.66
33.08 32.11
2.80 39.96 32.24
-0.5 -0.46
8.42 -1.02
-0.45 9.99 1.13
-0.5 -0.54 -9.60 0.73
-0.55 -10.67 0.72
1.44
–
–
–
–
–
1.57
–
–
–
–
–
-0.2
1
0.4
0.3
0.7
0.8
-0.3
-0.4
0.3
0.4

Multivariate longitudinal parameter estimates
-0.19
2.80
0.10
-0.20 0.11 0.08
0.66
-33.60 11.54
0.67 -33.22 11.31
0.29 -27.42 4.50
0.31 -23.54 3.52
0.24 -19.74 1.63
0.24 -19.80 1.64
0.74
6.04
0.39
0.75
6.55 0.35
0.90
12.36 1.70
0.91 14.10 1.66
-0.15 49.99 10.08
-0.14 52.77 8.44
-0.20 49.99 10.08
-0.19 50.63 10.27
0.30
-0.88 0.37
0.24 -1.94 0.06
0.32 -19.28 1.54
0.32 -19.78 1.58
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the survival sub-model, it is visible that Model SN outperforms Model N for the association parameters and baseline covariates except for

1,

2,

and

3.

Some parameters in the survival sub-model

are slightly underestimated, and some parameters are slightly overestimated in both models. Consequently, the simulation results verify the essential of accounting for skewness in the data. This
suggests that adopting the assumption of normal distribution may lead to inefficient inference and
inaccurate on fixed-effects of primary interest, particularly when data exhibit non-normal features.
3.6

Concluding discussion

In this chapter, we propose an MVJM approach with multiple longitudinal responses and survival processes under the Bayesian inference. The corresponding multivariate linear mixed-effects
model and Cox proportional hazard model are linked through the random-effects that characterize
the underlying individual-specific longitudinal process. Some common but essential data features
are also considered, such as non-normality, which may influence the diagnosis progression of the
true disease. Comparing with the classic frequentist’s methods, a full Bayesian inference approach
is powerful when the dimension of parameters is high in such complicated multivariate joint modeling. Although the joint modeling for longitudinal and time-to-event data has been an active
area of statistical methodological study [13, 43, 46, 86, 87], this paper extends to consider joint
modeling of multivariate longitudinal outcomes with SN distribution and Cox proportional hazard
model, accounting for multiple data features simultaneously. Although this study is motivated by
diabetes study data, the innovations of the developed multivariate joint models and methods help
practitioners to analyze complicated multiple longitudinal outcomes and time-to-event data under
a wide range of considerations.
The proposed MVJM has certain advantages compared to traditional joint models. First, the
majority of joint models only focus on a single longitudinal outcome associated with the time-toevent endpoint. However, in many clinical and observational studies, multiple longitude outcomes
are collected together, and they may be highly correlated. The MVJM we proposed can reduce
the bias and increase the efficiency in parameter estimation. These exciting findings have critical
clinical indications. Our results suggest that there are a positive association between rates of growth
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and risk of T1D (i.e., there is an increased risk of T1D for larger height and weight at baseline).
Secondly, it is of significance to measure longitudinal outcomes height and weight appropriately
when they exhibit skewness and heavy tails, this study considers two statistical models (Models
SN and N) with different scenarios. We find that Model SN is favorable to model N. In model SN,
the estimates of skewness parameter

1

and

2

are statistically significant for height and weight,

indicating that the left-skew with heavy tail exists in height and weight measurements. Therefore,
the MVJM with the SN distribution provides more efficient and accurate parameter estimation,
so it serves as a better alternative to the normal (symmetric) distribution-based model, which is
broadly assumed in statistical researches.
In summary, we apply the Bayesian MVJM approach to analyze the motivating pediatric diabetes study. Our results demonstrate the use of MVJM for the examination of how the patterns
of height and weight trajectories are associated with the risk of T1D. Further, our results suggest
that it is essential to consider MVJM with the skewed distribution in order to achieve less biased
and more accurate estimates in the presence of a non-normal feature in height and weight measurements. Although the motivation for this chapter is arose from a T1D study, the basic concepts
of the developed Bayesian MVJM approach have generally more widespread applications in practice, when the two different sources among longitudinal measures over time are dependent; and
between longitudinal and survival variables are presented and the relevant technical specifications
are met. Our models have the inherent to be farther extended to more complicated models. For
example, (i) we may consider the missing data mechanism by introducing a non-ignorable model
for longitudinal measurements [42, 43]. (ii) This article considers a single-type survival event
only. In the presence of multiple “failure” types of events, the proposed MVJM can be extended
to accommodate competing risks survival data [25, 41]. (iii) We may consider the multivariate
piecewise (change-points) joint modeling and nonlinear function-based joint modeling. These interesting topics are beyond the focus of this article, but are warranted in our research pipeline under
investigation.
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Chapter 4
Joint modeling analysis of multivariate skewed-longitudinal and time-to-event data with
application to primary biliary cirrhosis study

4.1

Introduction

Primary biliary cirrhosis (PBC), recently known as primary biliary cholangitis, is a relatively rare
disease caused by inflammatory destruction of the small bile ducts from the liver. Eventually,
this pressure build-up will harm the bile ducts leading to liver cell damage and cirrhosis. The
cause of PBC is unknown, but because the body’s immune system attacks its own cells, it is most
likely thought to be an autoimmune disease. In this disease, the bile ducts are under attack and
are destroyed [31]. Women are more likely than men to have PBC, it is most often in the woman
above the age of 40 [54, 72].
Mathematical models based on PBC clinical study have been developed to predict disease progression. Cox proportional hazards model for survival analysis was performed to identify the two
significant biomarkers, Alkaline Phosphatase and Serum Bilirubin, regarding the risk of an event
(death or liver transplantation) for patients diagnosed with PBC [55, 54]. An increase in the levels
of these biomarkers was positively associated with the hazards of PBC patients. Typically, serum
bilirubin concentration was the best prognostic biomarker from all the other laboratory measurements. When the serum bilirubin exceeded 6.0 (mg/dl), the survival time was around 25 months
[73]. Many other risk covariates such as age, sex, ascites, prothrombin were also used to prognostic
models for PBC. However, there were several potential limitations of the previous approach-based
survival analysis when the covariates were repeatedly measured over time. Firstly, only capture the
biomarker observation until a certain time point, mean value or at particular time point was taken
into account, but not all observations over time were take into account; using only one observation
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of the biomarker obviously discarded useful information about the biomarker and its trajectory.
Secondly, the inter relationships between longitudinal and time-to-event processes were ignored.
Thirdly, longitudinal growth trajectory as a time-varying covariate was not fully considered to assess the effect of longitudinal measures on the risk of the event. The longitudinal processes will
affect the hazard of survival; therefore, an appropriate statistical model is needed to capture the
unobservable quantities of the growth profile and overall growth trajectory for association with
risk of death for PBC patients. The joint modeling had been applied to remedy the deficiencies.
The joint modeling approach can capture the rate of change in the biomarker levels, which
contains the differences between patients and also the difference over time for the same patient.
Joint modeling of longitudinal and survival data is an active area of scientific fields such as in
biology, biomedical and clinical research, since it allows simultaneous analysis of longitudinal
(repeated) measurements and time-to-event (survival) outcome [37, 10, 79, 66, 69, 45, 88]. For
example, Allen et al. [2] inspected the relationship between five longitudinally collected cytokines
(Interleukin (IL)-6, IL-8, growth-related oncogene-1 (GRO-1), vascular endothelial growth factor
(VEGF), and hepatocyte growth factor (HGF)) measured from serum plasma and survival, focused
on whether the values of these multiple cytokines were associated with survival. Survival outcome
is always associated with multiple longitudinal outcomes. Important features in clinical studies of
this type are that there might be a relatively large number of biomarkers [1, 11, 14, 15, 59, 28, 50,
63, 64, 70, 76, 77] , these biomarkers are subject to sizable measurement error due to laboratory
error and biological variation and which may be significantly correlated, like the PBC study from
the Mayo clinic [62], patients with PBC were followed longitudinally and multiple longitudinal
biomarkers were measured.
The PBC data collected at the Mayo Clinic between 1974 to 1984 [62] have been widely analyzed using joint modeling methods [1, 3, 20, 21, 40, 22, 24, 67]; researchers that risk of death
was significantly impacted by the logarithm of serum bilirubin levels. However, multiple longitudinal biomarkers were collected in the PBC study, it was important to understand the relationship
among these biomakers’ growth over time and the risk of PBC death. The adoption of a multivariate joint modeling (MVJM) to reassess the impact of multiple serum levels on the risk of
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death will reduce potential bias imposed by ignoring the correlation between the longitudinal exposures pervading in the more commonly used univariate joint modeling (UVJM) approach. Joint
modeling considering multiple longitudinal biomarkers of prognosis simultaneously can provide
more accurate prediction of survival, modeling their interrelationship, correlation and uncertainty.
Moreover, in traditional linear mixed-effects models, random errors are often under a normality
assumption because of the computational convenience and mathematical tractability. However,
normality assumption may not be realistic. Alternatively, skew-normal (SN) distribution should
be more appropriate to model the skewed data [47, 71]. The aim of this chapter is to demonstrate
an introductory overview on MVJM approach for longitudinal exposures and time-to-death in a
specific application to Mayo Clinic PBC data, which enables fitting of such model have high dimensional longitudinal exposures. Here, we examined the association of the three longitudinal
biomarkers serum bilirubin (SB), serum albumin (SA) and serum Glutamic-Oxaloacetic transaminase (SGOT) with skew-normal (SN) distribution (i.e., estimated bilirubin at baseline and change
rate over time) with the risk of death simultaneously; the result of UVJM with SN distribution was
presented in Supplemental for comparison.

4.2
4.2.1

Methods
Primary biliary cirrhosis (PBC) background and datasets

Chapter 2 section 2.2 has briefly described the PBC dataset that motivated this application research.The original clinical protocol for these patients specified visits at 6 months, 1 year, and
annually thereafter. This is an ideal dataset to illustrate the various features of MVJM.
4.2.2

Longitudinal exposures and survival outcome

Patients with PBC had abnormalities in several blood tests, such as elevated levels of SB. Several
laboratory tests had a baseline measurement and were followed longitudinally at 6 months and at
yearly intervals thereafter. Data collected at each lab visit include: total SB, SA, SGOT, gender,
presence of ascites and other covariates for the patients. Due to the skewness of the observed
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biomarkers, specially SB, we took the natural logarithm of them and used the logarithms of these
biomarkers for the remainder of this analysis. Figure 8 (A-C) showed the randomly picked 50
sample trajectories of natural logarithms of SB, SA and SGOT; moreover, Kaplan-Meier (K-M)
survival curve depicted in Figure 8 (D) may be dependent on the multivariate longitudinal exposures.
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Figure 8. Profiles of observed ln(SB), ln(SA) and ln(SGOT) measurements up to year at death
or most recent clinic visit for 50 randomly selected patients (A-C). Kaplan-Meier (K-M) survival
curve for death as an event (D).
Normally, the longitudinal measurements are modeled using the linear mixed-effects model for
a continuous and normally distributed outcome [52]. The subject-specific random-effects in this
mixed-effects model are included in the relative risk model. The random-effects not only account for the association between the longitudinal and survival outcomes, but also the correlation
between the repeated measurements in the longitudinal process. In the PBC dataset, multiple
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longitudinal outcomes had been recorded. Extending the UVJM to accommodate these multiple
longitudinal exposures allows us to incorporate more information and thereby improves the prognostic ability of the modeling. In this analysis, we were interested in the association between the
three longitudinal biomarkers (SB, SA, SGOT) and the risk of death.
We observed the heterogeneity of each of the biomarkers for these patients. In clinical study,
longitudinal exposures of the measurements of SB, SA and SGOT were usually measured with
substantial errors. Meanwhile, after taking the natural logarithms of the three longitudinal exposures, they were still skewed. Diverse linear mixed-effects models were discussed in the literature,
but the majority of them assume the error term follows normal distribution which may lack the
robustness against departures from normality in practice [12, 60, 81]. In order to make a robust
inference and relax the normality assumption, the model was assumed to follow SN distribution.
We offered an MVJM with subject-specific random intercept, random slope and quadratic of year
and gender of the three serum levels for the longitudinal sub-model; and these six subject-specific
random quantities were served as surrogate covariates in the survival sub-model. Therefore, an
appropriate statistical model was needed to capture all the different biomarkers trajectories with
the risk of death.

4.2.3

Multivariate joint modeling

There are two basic components of a joint modeling: the longitudinal component and the timeto-event (survival) component. In this regard, longitudinal measurements and survival outcome
should to be modeled simultaneously in order to account for uncertainty and all information from
both segments, and understand the associated relationship between the the risk for the event and
underlying longitudinal data. Figure 9 presented the underlying causal diagram for joint modeling mechanism. The MVJM with multiple longitudinal exposures and SN distribution here was
considered as an extension of a traditional UVJM.
The MVJM consisted of a multivariate linear mixed-effects model for longitudinal SB, SA and
SGOT exposures (the longitudinal sub-model) and a Cox proportional hazards model for the time
of death as the outcome (the survival sub-model), which linked through the common subject-
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Figure 9. Causal diagram of the underlying mechanism of MVJM for the longitudinal and survival processes: Rectangles denote observed data; ellipse denotes unobserved quantities; circles
denote unobserved (including subject-specific random bi ) terms and unknown parameters. The
arrows direct statistical dependencies. The causal chain of interest runs from longitudinal exposure yik (k = 1, 2, 3) to hazard i (ti ) for event, whereas yik (k = 1, 2, 3) does not “cause” event;
however, it is statistically related to event by its dependence on the unobserved random quantities
bi .
specific random-effects (intercepts and slopes) from the three functional forms to bring these two
data types together into a single (multivariate joint) model, enabling better inference of the correlation, interplay and association between multiple longitudinal and time-to-event data. Moreover, in
order to relax the normality assumption and make a robust inference, we assumed the multivariate
longitudinal model with SN distribution. Based on both clinical significance and model selection
criteria, we included the following covariates in the longitudinal sub-model: quadratic of year and
gender (male as reference). In the survival sub-model, we assessed the simultaneous associations
of the six subject-specific random baseline and change rate estimated from the longitudinal submodel as time-varying covariates with risk of death. The survival sub-model was also adjusted for
age at baseline, gender(male as reference), ascites(yes or no), hepatomegaly(yes or no), edema(yes
or no) and histologic stage

3 (yes or no).

As described above of a general multivariate linear mixed-effects model with SN distribution,
the following was the specific MVJM for analyzing three longitudinal exposures of SB, SA and
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SGOT measures and time-to-death outcome in our application to the Mayo Clinic PBC study:
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(4.1)

Specifically, where ln(SB), ln(SA) and ln(SGOT) are the respective natural logarithms of SB,
SA and SGOT observations for the ith subject at time yearij . The vector of random errors
✏3 = (✏1 , ✏2 , ✏3 )T ) follows a multivariate SN distribution with unknown variance-covariance matrix ⌃3 = (
and I ni

= 1, 2, 3), unknown skewness parameter matrix ⌃3 = diag( 1 , 2 , 3 )T ,
p
= (1, . . . , 1)T . Note that
2/⇡[ 3 ⌦ 1ni ] is specified here to make the SN distribution
2
0
kk0 )3⇥3 (k, k

with mean zero. bi = (bi01 , bi02 , bi03 , bi11 , bi12 , bi13 )T is a vector of random effects which follows
N6 (0, ⌃b ) with ⌃b being a covariance matrix. This longitudinal sub-model assumes the mean
baseline measurement, mean change rate and quadratic rate of year are different between male and
female. For the survival sub-model, where

= ( 1,

2,

3,

4,

5,

6)

T

is the vector of the param-

eters corresponding to the random-effects bi and the vector ↵ = (↵1 , ↵2 , ↵3 , ↵4 , ↵5 , ↵6 )T is the
coefficient paramters corresponding to the risk factors Z i which are age at baseline, gender (male
as reference), ascites (yes or no), hepatomegaly (yes or no), edema (yes or no) and histologic stage
3 (yes or no). In the PBC study data, after taking natural logarithms of the three longitudinal
exposures (SB, SA and SGOT), they still exhibits skewness and outliers as shown in Figure 2(B)
to (D). Thus, we assume the multivariate linear mixed-effects models with SN distribution. The
MVJM with SN distribution was applied to assess the simultaneous effects of the three longitudinal
biomarkers on risk of death.
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4.2.4

Bayesian analysis method

The MVJM considered here is an extension of a traditional UVJM with multiple longitudinal outcomes and skew-normal assumption. In order to relax the normality assumption and make a robust
inference, we assume the multivariate longitudinal model with skew-normal (SN) distribution. The
Bayesian inference approch has been detailed illustrated in Chater 3. Then, under the Bayesian inference, we need to specify ✓ = ( , , ↵, ⌃b , ⌃3 ,
parameters in the joint model (4.1), where

3

3)

T

as the collection of unknown population

= ( 1 , 2 , 3 )T is the vector of skewness parameters.

We assign weakly informative priors to ensure the property of posteriors.
In our data analysis, the fully Bayesian method via the Markov chain Monte Carlo (MCMC)
techniques for the skew-normal multivariate (in Chapter 1) was adopted for model fitting and data
analysis. The simultaneous statistical inference on all unknown model parameters can capture
the underlying association between the longitudinal responses and the time-to-event data. We
specified the values for the hyper-parameters in the prior distributions. Due to the absence of
historical data, we applied weakly informative prior distributions for the parameters in MVJM.
In particular, (i) each element of the population coeffcient vectors

, ↵ and

was taken to

be independent normal distribution N (0, 100); (ii) the priors for the variance covariance matrices ⌃3 and ⌃b were taken to be inverse Wishart distributions IW (diag(0.01, 0.01, 0.01), 4) and
IW (diag(0.01, 0.01, 0.01, 0.01, 0.01, 0.01), 7); (iii)for each of the skewness parameter
3,

1,

2

and

which represent natural logarithms of SB, SA and SGOT, respectively, followed the normal

distribution N (0, 100).
The fully Bayesian methodology using Markov Chain Monte Carlo (MCMC) techniques was
adopted for the MVJM fitting and data analysis using the R software with associated R2Winbugs
[75], and the program code is attached in Appendix B. When MCMC procedure was applied to the
PBC study data, convergence of the generated samples was assessed using standard tools within
WinBUGS software such as trace plots and Gelman-Rubin (GR) diagnostics [30]. Figure 10 shows
the trace plots, autocorrelation and dynamic version of GR diagnostic plots based on MVJM with
SN distribution for the representative parameters . All of these plots imply that the algorithm
convergence is reached. We observe from trace plots (left panel) that the lines of three different
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chains mix or cross in trace, implying that convergence is reached. In the autocorrelation plots
(middle panel) is also monitored, that autocorrelations are very low with a lag being 50, indicating
that convergence is reached. Furthermore, for the plots of GR diagnostics (right panel) where the
three curves are given: the middle and bottom curves below the dashed horizontal line (indicated by
the value 1) represent the pooled posterior variance (V̂ ) and average within-sample variance (Ŵ ),
respectively, and the top curve represents their ratio (R̂). It is seen that R̂ is generally expected to
be higher than one at the initial stage of the algorithms, but R̂ tends to 1, and V̂ and Ŵ stabilize as
the number of iterations increase, indicating that the algorithm has approached convergence.
When these criteria suggested the convergence of chains, we proposed that, after an initial number of 30,000 burn-in iterations of three chains of iterations of 60,000, every 30th MCMC sample
was retained from the next 10,000 for each chain. Thus, we can totally get 3,000 samples of targeted posterior distributions of the unknown parameters for statistical inference. Even though this
is a high-dimensional computation working load, the MCMC algorithm conducting by WinBUGS
program will have no trouble regarding convergence of a solution for the inverse of matrices and
parameter estimates in this application.

4.3

Results

4.3.1

Multivariate joint modeling with skew-normal assumption results

Table 5 and Figure 11 showed the results of joint analysis for three longitudinal SB, SA, and
SGOT levels in natural log-transformed and time-to-death of PBC data based on the MVJM with
SN distribution. We fitted a multivariate linear mixed-effects model for each biomarker with a
patient-specific baseline value and patient-specific change rate with covariates quadratic term of
year and gender. It was shown from the results summarized in the upper half of Table 5 that in
the longitudinal sub-model, the estimated results indicated the skewness in SB (
(

2

=

0.03) and SGOT (

3

1

= 0.42), SA

= 0.095) after taking natural logarithms were estimated to be signif-

icant. This indicated that after the natural log-transformed of the three biomarkers, the skewness
with lightly right tail of the SB and SGOT, and the fair lightly left tail of SA remained. Thus, it
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Figure 10. Convergence diagnostics with three Markov chains as obtained from the WinBUGS software for representative parameters: trace plots (left panel); autocorrelation plots (middle panel);
Gelman-Rubin (GR) diagnostic plots (right panel), where the middle and bottom curves below the
dashed horizontal line (indicated by the value one) represent the pooled posterior variance (V̂ ) and
average within-sample variance (Ŵ ), respectively, and the top curve above the dashed horizontal
line represents their ratio (R̂).
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might suggest that accounting for an MVJM with the skewness distribution assumption provided a
better fit to the data which exhibit skewness and, in turn, gave more reliable estimates of the parameters in comparison with its counterpart where the normal distribution is assumed. The estimated
results of fixed-effects presented in Table 5 indicated that the growth rate of SB, SA and SGOT
ˆ = 0.601 +
with covariates quadratic term of year and gender might be approximated by ln(SB)
2.413year + 0.523year2
ˆ
and ln(SGOT)
= 4.73

ˆ = 1.285
0.240gender, ln(SA)
0.005year + 0.502year2

0.47year

0.11year2

0.013gender,

0.019gender, respectively.

On average, ln(SB) increased linearly, about 2.41 per year over time, combined a 0.52 acceleration; ln(SA) decreased linearly, about 0.47 per year over time, combined a 0.11 deceleration; and
ln(SGOT) decreased linearly, about 0.005 per year over time, combined a 0.50 acceleration. The
quadratic of year was all significant, gender was not significantly associated for the longitudinal
sub-model of the MVJM analysis.
For the parameters of the survival sub-model, Table 5 (bottom panel) presented simultaneous
effects of the three serum levels as time-varying covariates on the risk of death for the PBC patients.
The estimated hazard ratios of SB, SA and SGOT levels at baseline as time-varying covariates with
the risk of death were 2.390 (SB, with 95% CI:(1.429, 4.112)), 0.002 (SA, with 95% CI:(0.001,
0.029)) and 1.506 (SGOT, with 95% CI:(0.713, 3.340)); moreover, the estimated hazard ratios of
change rate of SB, SA and SGOT as time-varying covariates with the risk of death were 2.588
(SB, with 95% CI:(1.845, 3.967)), 0.191 (SA, with 95% CI:(0.037, 0.915)) and 0.490 (SGOT,
with 95% CI:(0.169, 1.116)) with adjustment for the additional covariates shown in Figure 11.
These findings implied a significantly positive association of the SB levels and a significantly
negative association of the SA levels with the risk of death for PBC patients. However, the SGOT
levels did not affect the risk of death for PBC patients significantly. To put it another way, a 1unit increase in the baseline of natural log-transformed SB levels increased the death risk more
than 2-fold (HR=2.390, 95% CI: (1.429, 4.112)), and a 1-unit increase in change rate of natural
log-transformed SB levels increased the death risk approximately 2.59-fold (HR=2.588, 95% CI:
(1.845, 3.967)). There was 80.9% (HR=0.191, 95% CI:(0.037, 0.915)) reduction in hazard of death
relative to a 1-unit increase in change rate of natural log-transformed SA levels, and indicating that

46

Table 5 Results from joint analysis for three longitudinal serum levels and risk of death based on
MVJM with SN distribution.
Parameter

PM

SD

95%CI
HR 95%CI
Multivariate longitudinal parameter estimates

ln(SB)
01
11
21
31
1

0.601
2.413
0.523
-0.240
0.420

0.135
0.180
0.221
0.146
0.030

(0.346, 0.849)
(2.014, 2.743)
(0.081, 0.955)
(-0.512, 0.045)
(0.354, 0.475)

1.285 0.021
-0.470 0.045
-0.110 0.051
-0.013 0.023
-0.030 0.010

(1.243, 1.327)
(-0.558, -0.381)
(-0.222, -0.001)
(-0.058, 0.032)
(-0.051, -0.011)

4.730
-0.005
0.502
-0.019
0.095
0.059
0.003
0.006
0.010
0.001
0.069

0.070
0.1-8
0.156
0.076
0.032
0.008
0.001
0.005
0.000
0.001
0.003

0.871
0.951
-6.147
-1.655
0.409
-0.712
0.042
-0.567
1.132
0.295
1.272
0.442

0.268
0.193
1.399
0.812
0.394
0.467
0.012
0.397
0.534
0.289
0.333
0.341

(4.594, 4.875)
(-0.221, 0.206)
(0.204, 0.818)
(-0.162, 0.136)
(0.034, 0.161)
(0.045, 0.076)
(0.000, 0.006)
(-0.004, 0.016)
(0.009, 0.011)
(-0.001, 0.002)
(0.063, 0.075)
Survival parameter estimates
(0.357, 1.414)
2.390 (1.429, 4.112)
(0.613, 1.378)
2.588 (1.845, 3.967)
(-9.151,-3.549)
0.002 (0.001, 0.029)
(-3.307,-0.089)
0.191 (0.037, 0.915)
(-0.338,1.206)
1.506 (0.713, 3.340)
(-1.777, 0.110)
0.490 (0.169, 1.116)
(0.019, 0.066)
1.043 (1.020, 1.069)
(-1.297, 0.247)
0.568 (0.273, 1.280)
(0.080, 2.183)
3.102 (1.084, 8.873)
(-0.285, 0.871)
1.343 (0.752, 2.389)
(0.624, 1.950)
3.568 (1.866, 7.029)
(-0.216, 1.120)
1.556 (0.806, 1.065)

ln(SA)
02
12
22
32
2

ln(SGOT)
03
13
23
33
3
2
11
2
12
2
13
2
22
2
23
2
33
1
2
3
4
5
6

↵1
↵2
↵3
↵4
↵5
↵6
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SA was a protective predictor for the risk of death for PBC patients. The effects of baseline
covariates in hazard were also presented in Table 5 and Figure 11. An increase in age of one year
(1.043 with 95% CI:(1.020, 1.069)) had a 4.3% increase in hazard for death. Patients with ascites
(HR=3.102, 95% CI:(1.804, 8.873)) were estimated to have 2.1 times higher hazard for death as
compared to patients without ascites; patients with edema (HR=3.568, 95% CI:(1.866, 7.029))
were estimated to have above 3-fold higher hazard for death than patients without edema. However,
the gender(HR=0.568, 95% CI:(0.273, 1.280)), hepatomegaly(HR=1.343, 95% CI:(0.752, 2.389))
and histologic(HR=1.556, 95% CI:(0.806, 1.065)) were not found to be significantly associated
with the risk of death.
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Figure 11. Hazard ratio (HR) in survival sub-model denoted by solid dot along with 95% CI of the
covariates using MVJM analysis. Here the baseline covariates are age, gender (Female vs. male
as reference), Ascites status (yes or no), hepatomegaly status (yes or no), edema (yes or no) and
histologic 3 (yes or no).

4.3.2

Univariate joint modeling results

Table 6 - Table 8 and Figure 12 - Figure 14 summarized the results of three univariate joint modeling (UVJM) with SN distribution for the single longitudinal biomarker measurements and risk of
death, separately. The results from the longitudinal sub-model were similar to their counterparts
from the MVJM with SN distribution reported in Table 5. In terms of statistical significance, the
differences in magnitudes of the parameter estimates were slightly different. However, In contrast,
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the results of the survival sub-model, Table 6 - Table 8 and Figure 12 - Figure 14 showed the effect
of the single biomarker as time-varying covariates of baseline and change rate on the risk of death,
respectively, adjusting for the covariates: age at baseline, gender, ascites, hepatomegaly edema and
histologic stage at baseline in the survival sub-model.
In the UVJM analysis as compared to the MVJM analysis, the estimated association of the
baseline and change rate of three biomarker measurements with risk of death might be biased and
possibly produce inconsistent findings, because it failed to take account the uncertainty caused by
the variations and correlations in the three longitudinally measured blood test results [1, 40]. In
this regard, we further fitted three UVJMs, separately, for each of the three biomarker (natural
logarithms of SB, SA and SGOT) and risk of death. We found that, for the survival sub-model, the
results were quantitatively and significantly different between the UVJM and MVJM analyses for
most of estimated parameters. This showed the importance of recognizing the uncertainty caused
by the additional variability and correlations in the tested values of SB, SA and SGOT. In particular,
some quantitative differences and/or inconsistent findings between the MVJM and UVJM analyses
were observed. For example, although significant associations of the change rate of all the three
biomarkers SB, SA and SGOT with the risk of death (SB: 2 =0.732 with 95% CI (0.558, 0.928),SA:
4 =-3.960

with 95% CI (-5.505, -2.703) and SGOT: 6 =1.327 with 95% CI (0.822, 1.985); see Ta-

ble 6 -Table 8) were found in the UVJM analysis, which were inconsistent with their counterparts
(SB:

2

SGOT:

= 0.951 with 95% CI(0.613, 1.378), SA:
6

4

=

1.655 with 95% CI( 3.307, 0.089) and

0.712 with 95% CI( 1.777, 0.110); see Table 4) in the MVJM analysis, the esti-

=

mated association parameters

2,

4,

6

were quantitatively different; in contrast, a significantly

positive association of the change rate of natural logarithms of SGOT levels with the risk of death
was found (
(

6

=

6

= 1.327; Table 8) in the UVJM analysis, while we could not confirm this finding

0.712; Table 5) in the MVJM analysis. These findings indicated that the UVJM analysis

might produce biased estimates [1, 40], since UVJM failed to consider about the correlation among
these three biomarkers.
In addition, the standard deviation (SD) for the association parameters of change rate of SB
(SD=0.094), SA (SD=0.724) and SGOT (SD=0.295) with the risk of death in the UVJM analyses
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were smaller than their counterparts SB (SD=0.193), SA (SD=0.812) and SGOT (SD=0.467) in the
MVJM analysis. This finding provided further evidence that the UVJM analysis had a potential
problem in that uncertainty, caused by the additional variability and correlations in observed levels
of natural logarithms of SB, SA and SGOT, was not taken into account, implying that the SDs were
underestimated in the three UVJM analyses and, in turn, might produce false significant results.
Table 6 Results from the joint analysis for longitudinal SB levels and risk of death based on UVJM
with SN distribution.
Parameter

PM

SD

95%CI

HR

95%CI

Univariate longitudinal parameter estimates
ln(Serum Bilirubin)
01
11
21
31
1

1
2

↵1
↵2
↵3
↵4
↵5
↵6

0.685
2.401
0.603
-0.330
0.444
1.230
0.732
0.046
-0.670
0.742
0.476
1.101
0.571

0.155
0.216
0.208
0.165
0.031

(0.374, 0.978)
(1.972, 2.829)
(0.197, 1.002)
(-0.639, 0.008)
(0.378, 0.501)

0.197
0.094
0.012
0.396
0.515
0.256
0.306
0.315

Survival parameter estimates
(0.860, 1.636)
3.412 (2.364, 5.135)
(0.558, 0.928)
2.079 (1.746, 2.529)
(0.023, 0.070)
1.047 (1.023, 1.073)
(-1.455, 0.086)
0.512 (0.233, 1.090)
(-0.243, 1.758)
2.099 (0.784, 5.801)
(-0.006, 0.975)
1.610 (0.994, 2.651)
(0.492, 1.701)
3.007 (1.635, 5.479)
(-0.037, 1.205)
1.770 (0.964, 3.337)
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Figure 12. Hazard ratio (HR) in survival sub-model denoted by solid dot along with 95% CI of the
covariates to adjust the random effects of the SB levels as time-varying covariates on risk of death
using UVJM analysis.

Table 7 Results from the joint analysis for longitudinal SA levels and risk of death based on UVJM
with SN distribution.
Parameter

PM

SD

95%CI

HR

95%CI

Multivariate longitudinal parameter estimates
ln(Serum Albumin)
02
12
22
32
2

3
4

↵1
↵2
↵3
↵4
↵5
↵6

1.260 0.023
-0.457 0.040
-0.012 0.054
0.011 0.024
-0.140 0.005

(1.213, 1.306)
(-0.535, -0.377)
(-0.118, 0.096)
(-0.037, 0.061)
(-0.150, -0.131)

-7.853
-3.960
0.015
-0.809
0.992
0.480
0.490
0.139

Survival parameter estimates
(-10.980, 4.862)
0.000 (0.000, 0.008)
(-5.505, -2.703)
0.019 (0.004, 0.067)
(-0.007, 0.039)
1.015 (0.993, 1.040)
(-1.543, -0.104)
0.446 (0.214, 0.902)
(-0.138, 2.179)
2.697 (0.871, 8.873)
(-0.057, 1.026)
1.616 (0.944, 2.790)
(-0.059, 1.032)
1.632 (0.942, 2.807)
(-0.455, .0734)
1.149 (0.634, 2.082)

1.579
0.724
0.012
0.369
0.600
0.276
0.286
0.308

51

Hazard Ratio

7.5

5.0

2.5

0.0
gamma3

gamma4

age

sex

ascites

hepatomegaly

edem

histologic

Figure 13. Hazard ratio (HR) in survival sub-model denoted by solid dot along with 95% CI of the
covariates to adjust the random effects of the SA levels as time-varying covariates on risk of death
using UVJM analysis.
Table 8 Results from the joint analysis for longitudinal SGOT levels and risk of death based on
UVJM with SN distribution.
Parameter

PM

SD

95%CI

HR

95%CI

Multivariate longitudinal parameter estimates
ln(SGOT)
03
13
23
33
3

5
6

↵1
↵2
↵3
↵4
↵5
↵6

4.789
0.001
0.306
-0.089
0.280
1.866
1.327
0.060
-0.577
1.058
0.587
0.562
0.586

0.082 (4.624, 4.947)
0.111 (-0.219, 0.214)
0.154 (-0.011, 0.600)
0.087 (-0.260, 0.085)
0.024 (0.229, 0.324)
0.371
0.295
0.014
0.351
0.515
0.249
0.290
0.289

Survival parameter estimates
(1.133, 2.571)
6.462 (3.105, 13.079)
(0.822, 1.985)
3.770 (2.274, 7.279)
(0.034, 0.087)
1.062 (1.035, 1.091)
(-1.273, 0.108)
0.562 (0.280, 1.114)
(0.032, 2.082)
2.881 (1.032, 8.020)
(0.094, 1.081)
1.798 (1.099, 2.948)
(-0.034, 1.129)
1.754 (0.966, 3.093)
(0.030, 1.163)
1.797 (1.030, 3.200)
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Figure 14. Hazard ratio (HR) in survival sub-model denoted by solid dot along with 95% CI of the
covariates to adjust the random effects of the SGOT levels as time-varying covariates on risk of
death using UVJM analysis.
4.3.3

Multivariate joint modeling with normal assumption results

Table 9 and Figure 15 summarize the results of the MVJM with the normal distribution for random errors analysis for the three longitudinal biomarker measurements and risk of death. The
results from the longitudinal sub-model were similar to their counterparts from the MVJM with
skew-normal assumption analysis reported in Table 4. The differences in magnitudes of the
parameter estimates were negligible in terms of statistical significance. For the magnitudes of
the variance covariance of the random errors were relatively more minor and all the skewness
parameters( 1 , 2 and 3 ) were statistically significant for the MVJM with skew-normal assumption.
In contrast, however, for the results of the survival sub-model, Table 9 and Figures 15 presented
the effect of the three biomarkers with normal assumption as time-varying covariates(baseline and
change rate) on the risk of death, respectively, adjusting for the covariates: age at baseline, sex,
ascites, hepatomegaly edema and histologic stage at baseline in the survival sub-model.
In the MVJM with normal assumption analysis as compared to the MVJM with skew-normal
assumption analysis, the estimated association of the baseline and change rate of three biomarker
measurements with risk of death might be biased and possibly produce inconsistent findings, because it fails to take into account the skewness and heavy tail in the three longitudinally measured
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blood test results; even after taking the natural logarithm of three biomarkers, normality assumption may not be realistic. In this regard, we further fitted MVJM with the normal assumption of
the three biomarkers (natural logarithms of Serum Bilirubin, Serum Albumin and SGOT) levels
and risk of death. We found that, for the survival sub-model, the results were quantitatively and
significantly different between the MVJM with different random error assumptions analyses for
most of the estimated parameters. This showed the importance of recognizing the skew-normal
(SN) distribution (see Chapter 1 in detail) should be more appropriate to model the skewed data
[71] in the tested values of SB, SA and SGOT. In particular, some quantitative differences and/or
inconsistent findings between the MVJM with normal assumption and MVJM with skew-normal
assumption analyses were observed. For example, although significantly associations of the random effects of baseline and change rate for the biomarkers SB and SA with the risk of death (SB:
1

= 0.960 with 95% CI (0.381, 1.493);

with 95% CI (-10.136, -3.286);

4

=

2

= 0.954 with 95% CI (0.536, 1.560), SA:

3

=

6.437

1.606 with 95% CI (-3.187, -0.112); see Table 6 -Table 8)

were found in the MVJM with normal assumption analysis, which all the absolute value of the
parameter estimates for these random effects were larger with their counterparts (SB:
with 95% CI (0.357, 1.414);
95% CI (-9.151, -3.549);

4

2

=

= 0.951 with 95% CI (0.613, 1.378), SA:

3

=

1

= 0.871

6.147 with

1.655 with 95% CI (-3.307, -0.089) ; see Table 4) in the MVJM

with skew-normal assumption analysis, the estimated association parameters ( 1 ,

2,

3,

4)

were

quantitatively different; in contrast, a insignificantly positive association of ascites with the risk of
death was found (Ascites = 0.830; see Table 8) in the MVJM with normal assumption analysis,
while we found ascites was significantly associated with risk of death (Ascites = 1.132; Table 4)
in the MVJM analysis. These findings indicated that the MVJM with normal assumption analysis
might produce biased estimates.
In addition, the standard deviation (SD) for the association parameters of random effects of baseline and change rate of SB (SD( 1 )=0.286, SD( 2 )=0.243), SA (SD( 3 )=1.731, SD( 4 )=0.789)
and SGOT (SD( 5 )=0.463, SD( 1 )=0.572) with the risk of death in the MVJ with normal assumption analysis were bigger than their counterparts SB (SD( 1 )=0.268, SD( 2 )=0.193), SA
(SD( 3 )=1.399, SD( 4 )=0.812) and SGOT (SD( 5 )=0.394, SD( 6 )=0.467) in the MVJM with
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Table 9 [
Results for MVJM with normal distribution]Results from joint analysis for three longitudinal serum levels
and risk of death based on MVJM with normal distribution.

Parameter

PM

SD

95%CI

HR

95%CI

Multivariate longitudinal parameter estimates
ln(Serum Bilirubin)
01
11
21
31

0.635 0.131
2.350 0.179
0.753 0.212
-0.272 0.147

(0.373, 0.868)
(1.990, 2.681)
(0.355, 1.167)
(-0.550, -0.005)

1.285 0.022
-0.470 0.041
-0.127 0.056
-0.014 0.024

(1.239, 1.328)
(-0.553, -0.391)
(-0.239, -0.015)
(-0.061, 0.036)

4.753
-0.016
0.541
-0.044
0.121
-0.002
0.020
0.010
0.000
0.073

0.069
0.113
0.149
0.076
0.005
0.001
0.003
0.000
0.001
0.003

0.960
0.954
-6.437
-1.606
0.388
-0.935
0.046
-0.513
0.830
0.343
1.257
0.439

0.286
0.243
1.761
0.789
0.463
0.572
0.014
0.428
0.556
0.289
0.377
0.355

(4.616, 4.890)
(-0.244, 0.203)
(0.252, 0.830)
(-0.198, 0.095)
(0.112, 0.131)
(-0.003, 0.000)
(0.015, 0.025)
(0.010, 0.011)
(-0.002, 0.001)
(0.068, 0.079)
Survival parameter estimates
(0.381, 1.493)
2.612
(0.536, 1.560)
2.597
(-10.130, -3.286)
0.002
(-3.187, -0.112)
0.201
(-0.471, 1.358)
1.474
(-2.213, 0.017)
0.393
(0.020, 0.073)
1.047
(-1.345, 0.329)
0.599
(-0.254, 1.953)
2.293
(-0.247, 0.903)
1.409
(0.539, 1.995)
3.515
(-0.234, 1.146)
1.551

ln(Serum Albumin)
02
12
22
32

ln(SGOT)
03
13
23
33
2
11
2
12
2
13
2
22
2
23
2
33
1
2
3
4
5
6

↵1
↵2
↵3
↵4
↵5
↵6
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(1.463, 4.450)
(1.710, 4.759)
(0.000, 0.037)
(0.041, 0.894)
(0.624, 3.888)
(0.109, 1.017)
(1.020, 1.076)
(0.261, 1.389)
(0.776,7.050)
(0.782, 2.467)
(1.713, 7.352)
(0.791, 3.146)
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Figure 15. Hazard ratio (HR) in survival sub-model denoted by solid dot along with 95% credible
interval (CI) of the covariates to adjust the random effects of the three Serum levels as time-varying
covariates on risk of death using MVJM with normal assumption analysis.
skew-normal analysis. This finding provided further evidence that the MVJM with normal assumption analysis had a potential problem in that exhibiting skewness in observed levels of natural
logarithms of SB, SA and SGOT, was not taken into account, implying that the SDs were overestimated in the MVJM with normal assumption analysis and, in turn, might produce false significant
results. MVJM analysis with the SN distribution provides a better fit to the data, which exhibits
skewness and, in turn, gives more reliable estimates of the parameters.
4.4

Concluding discussion

To simultaneously analyze three longitudinal exposures and time-to-event data, we have presented
the MVJM approach. However, joint modeling is essential in many applications. It is well known
within the biostatistical literature, allowing more accurate inference of the dependency and association between these two types of data. This paper extended the traditional joint modeling application to consider joint modeling of multivariate longitudinal exposures with skewness distribution
and Cox proportional hazard model, considering multiple data characteristics simultaneously. The
principal benefit of this MVJM with SN distribution over traditional UVJM analysis is its efficient
use of helping practitioners to analyze complicated multiple longitudinal exposures and time-toevent data under a wide range of considerations, which enables precise inference. By applying this
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advanced MVJM method, we could obtain more precise and reliable estimates by considering the
highly correlated characteristics of the different serum levels and infer insights into the complex
relationships between various longitudinal exposures and the risk of death for PBC patients.
We have reported the MVJM with SN distribution of a dataset from examining the progress
of PBC in 259 patients in the Mayo Clinic to assess the dependency and association between
the multiple longitudinal exposures over time and time-to-death outcome. The results from this
MVJM revealed that both the baseline and change rate of SB trajectory over time were positively
associated with the risk of death; both the baseline and change rate of SA trajectory over time
were negatively associated with risk of death, but no significant association was found between the
SGOT trajectory and death. From a clinical perspective, these estimates were broadly in line, that
higher SB was associated with a higher risk of mortality. In contrast, higher SA was associated
with a lower risk of mortality. This study provides physicians a more flexible and dynamic model
to discriminate patients using multiple biomarkers. Improving the knowledge about the course of
PBC and its biomarkers is essential for the development and approval of new therapies.
To our knowledge, under the framework of Bayesian joint modeling for longitudinal and timeto-event data, no studies have tested multivariate longitudinal data based on SN distribution of
biomarkers trajectory over time to predict survival event for the PBC study. Despite these strengths,
the following notes should be made in our study. First, including the second-order polynomial in
the longitudinal component, so we only select patients with at least three or more observations. As
a result, the sample size was different from that in the analysis done by other researchers. Second,
from the trajectory plots, the model specification in a linear fashion may be inadequate to explain
the time course of the repeated SA, SB, and SGOT measurements, and the more complicated
models, such as the piecewise and nonlinear function-based models, should be analyzed. Finally,
male patients were weighted with only light underwear on, and thus, their biomarkers value would
be affected by lighter weight measurement, while undressing was not requested in female patients.
This might introduce a slight systematic bias. However, since 88.03% PBC patients were female
in this study, which might indicate the majority of PBC patients were female.
Using an UVJM with SN distribution where only one longitudinal exposure serum was assessed
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as compared to MVJM with SN distribution, the estimated association of the time-varying serum
levels with risk of death were biased which generally attenuates the risk estimates to the null, because it failed to take into account the uncertainty caused by the variations and correlations in the
three longitudinally measured serum levels. We further explored the UVJM approach in the PBC
data by fitting three UVJMs, separately, for each of the three serum (SB, SA and SGOT) levels and
time to death. We found that, for the survival sub-model, the results showed considerably quantitative differences between the UVJM and MVJM analyses for most of the estimated parameters.
This indicated the importance of recognizing the uncertainty caused by the additional variability
and correlations in the observed values of SB, SA and SGOT levels.
In summary, the PBC data analysis using this MVJM with SN distribution has certain advantages compared to classical joint modeling. First, most joint modeling only focuses on the univariate longitudinal outcome associated with the time-to-event endpoint. However, in practice,
multiple longitude exposures are likely to be collected together, and they may be highly correlated
in clinical and observational studies. The MVJM analysis can reduce the bias and increase the
efficiency in parameters estimation. The predictive capability will be improved by incorporating
all sources of the data. These interesting findings have important clinical indications and lead to
more informative inferences for the purpose of medical decision-making. Our results suggested
that the biomarkers (SA, SB) had a significant association with the risk of death. The MVJM
analysis is suitable in any circumstance where one wishes to investigate the association of survival
outcomes and longitudinal outcomes. Secondly, since it was important to measure SB, SA, and
SGOT appropriately when they exhibited skewness and heavy tails, even though after we took the
natural logarithms, this analysis considered the estimation of skewness parameters

1,

2

and

3

were statistically significant for ln(SB), ln(SA) and ln(SGOT), indicating that the skewness exists
in these biomarkers measurements. The MVJM approach with the SN distribution provided more
efficient and accurate parameter estimation as compared to existing joint modeling for the PBC
study.
To conclude, the MVJM with skewness distribution analysis is an improvement over traditional
joint modeling and survival model because they consider all the longitudinal associated observa-
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tions of covariates that are predictive to the survival outcome. This MVJM method can be applied
to wide varieties of research settings to obtain better parameter estimation for future prediction in
medical research in comparison with traditional UVJM since they are considered to account for
individual variability. These predictions can provide relatively accurate characterizations of individual disease progression, which might be important for the timing of interventions, qualification
for appropriate treatments, and additional other analysis. Although medical researchers’ application of MVJM is limited uptake, it is useful and suitable to a broader field in a clinical application
when multivariate longitudinal exposures and time-to-event data are available.
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Chapter 5
Conclusion and future research

To conclude, we proposed a multivariate joint modeling with SN distribution and an application
study under the Bayesian framework, including skewness of random errors and multivariate longitudinal exposures, which are all considered at the same time. Even though this is inspired by
the pediatric diabetes study, these methods and novel models have wider applications, and analyzing the complex longitudinal and survival data under relevant specifications is more flexible for
practitioners.
Traditionally, the joint modeling has not analyzed multivariate longitudinal exposures and under the skewness distribution and the survival rate simultaneously. This dissertation is a special
contribution in the biomedical field; it also contributes to the development of Bayesian inference
statistical method designed to jointly model multivariate longitudinal outcomes and survival outcome. We want to emphasize that, except for the methodological results and the application study
that have been explained in detail in the previous chapters, this thesis has a specific contribution to
the joint modeling study.
There are a lot of advantages to the MVJM we developed. Firstly, the MVJM can apprehend
the distinct associations between the survival outcome and multiple longitudinal exposures. For
instance, the PBC data results suggested that bilirubin was a risk predictor of death and albumin was a protective predictor of death for PBC patients. Secondly, with the application of SN
distribution, when it exhibits skewness and heavy tails, our joint models considered longitudinal
exposures random errors appropriately. According to the simulation, the estimate in skew distribution is proved to be more accurate. Thus, in consonance with the claim of “evidence-based
medicine” and “precision medicine”, MVJM will be capable of providing more information and
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evidence to the physicians, which will benefit their clinical treatment evaluation and decision makings. With the full Bayesian framework approach proposed, it is more robust when the dimension
of parameters in a complex joint modeling is excessive, it is acquired to obtain the point estimates
and 95% CI for parameters of interest. For inference of multivariate joint models, even though
the parameter and/or model identifiability is crucial, when a large number of parameters needed
to be calculated at once, it could be a difficult matter, especially when there are more than 4 random effects (individual-specific terms) in each model. Practically, the MCMC algorithm would
rapidly diverge when then models are indistinguishable. When implementing it during the study,
the MCMC algorithm would converge without issues and no potential identifiability problems are
observed.
Using the MCMC procedure, all the joint modeling in this report can be simply fitted using the
WinBUGS package interacted with R software which is widely available to the public. With this,
our application is more effective and accessible to all statisticians. But, because of the rigorous
computation for a complicating model approach, only small-scale replications for each joint modeling with various scenarios in the simulations, in turn, could be more biased. Even so, the results
of the simulations were valid, as the variation of each parameter of interest was insignificant. By
using parallel computing, this rigorous computation time could be minimized later on.
Statistical inference and mathematical modeling, there are integrated new technologies in this
research for application study with further follow-up studies. The complicated nature of the clinical
and biological study will naturally remain some challenges on the agenda for future research. The
joint models could be extended to even more complex matters. For instance, (i) by introducing the
simple non-ignorable model for missing mechanisms, we could think about the missing covariates;
(ii) competing risk processes and multivariate longitudinal exposures could be modeled together.
In the presence of multiple “failure” types of events, the proposed MVJM can be extended to
accommodate competing risks survival; (iii) We may consider the multivariate piecewise (changepoints) joint model and nonlinear function-based joint models; (iv) When the proposed model
implemented in a large dataset, an intensive computational effort is required, so the optimization
of the numerical and algorithms procedures may be required to have faster results. Additional
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validation may be required as these issues are very complicated and not the main focus of this
dissertation. While the issues are still in the study, we hope to have some results soon in the near
future.
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Appendix A
R and WinBUGS program codes for Model SN in Chapter 3

#####################################################################
#### R program code
#####################################################################
library(arm)
library(R2WinBUGS)
data<-list(......)
inits<-list() # Run three chains
inits[[1]]<-list(......)
inits[[2]]<-list(......)
inits[[3]]<-list(......)
parameters<-c(......)
hw.t1d.BVJM <-bugs(data, inits, parameters, "hw.t1d.BVJM_SN.txt",
n.chains=3,
n.thin=20, n.iter=30000,n.burnin=10000,bugs.seed=654321,
bugs.directory="C:\\Users\\WinBUGS14",DIC=TRUE,debug=TRUE)
#####################################################################
#### Start WinBUGS code: hw.t1d.BVJM_SN.txt
#####################################################################
model {
for (i in 1:n)
# n total number of subjects
{
# random effects for bivariate model with normal distribution
for (k in 1:4)
{ b1[i,k] <- 0}
b[i,1:4] ˜ dmnorm(b1[i,1:4],Omega[,])
## individual parameters
beta11[i] <- beta[1]+b[i,1]
beta21[i] <- beta[2]+b[i,2]
beta31[i] <- beta[3]+b[i,3]
beta41[i] <- beta[4]+b[i,4]
} #End of i
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## (1) Event time models(Cox regression model)###
for(i in 1:n)
# set up data
{
for(j in 1:Tnum)
#Tnum=42
{
# risk set = 1 if obs.t >= t
risk[i,j] <- step(obs.t[i] - t[j] + eps)
# counting process jump = 1 if obs.t in [ t[j], t[j+1] )
#
i.e. if t[j] <= obs.t < t[j+1]
dN[i, j] <- risk[i, j] * step(t[j + 1] - obs.t[i] - eps)*fail[i]
}
}
# Cox regression model
for(j in 1:Tnum)
{
for(i in 1:n)
{
dN[i, j] ˜ dpois(Idt[i, j])
# Likelihood
Idt[i, j] <- risk[i, j] *
exp(theta[1]*beta11[i]+theta[2]*beta21[i]+
theta[3]*beta31[i]+theta[4]*beta41[i]+
alpha[1]*T[i,5]+alpha[2]*T[i,6]+alpha[3]*T[i,7]+
alpha[4]*T[i,8]+alpha[5]*T[i,9]+alpha[6]*T[i,10])*dL0[j] #Intensity
}
dL0[j] ˜ dgamma(mu0[j], c0)
mu0[j] <- dL0.star[j]*c0
# prior mean hazard
}
#####coefficients
c0 <- 0.1
r <- 5
for (j in 1 : Tnum) { dL0.star[j] <- r * (t[j + 1] - t[j]) }
for(j in 1:N)
# N=total number of longitudinal measurements
{
## (2) Modelling bivariate longitudinal model with SN distribution
wh[j,1]<-beta11[y[j,1]]+beta21[y[j,1]]*y[j,3]+gamma1[1]*y[j,3]*y[j,3]+
gamma2[1]*y[j,6]
wh[j,2]<-beta31[y[j,1]]+beta41[y[j,1]]*y[j,3]+gamma1[2]*y[j,3]*y[j,3]+
gamma2[2]*y[j,6]
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#y[j,1]=id, y[j,3]=ageyrs, y[j,6]=female
##SN-distribution
w[j] ˜ dnorm(0, 1) I(0,)
##SN
mean.wh[j,1]<-wh[j,1]+delta1*(w[j]-0.798)
mean.wh[j,2]<-wh[j,2]+delta2*(w[j]-0.798)
y[j,4:5]˜dmnorm(mean.wh[j,1:2], Omega1[,])
Y.pred[j,1:2]˜dmnorm(mean.wh[j,1:2], Omega1[,])
#Fitted values and residuals
fit.h[j]
<- mean.wh[j,1]
resid.h[j] <- y[j,4]-fit.h[j]
# sresid.h[j] <- sqrt(Omega1[1,1])*resid.h[j]
# squares of residuals of height
ssr.h[j] <- pow(resid.h[j],2)
# squares of predicted value of height
ssr.Ph[j] <- pow((Y.pred[j,1]-y[j,4]),2)
fit.w[j]
<- mean.wh[j,2]
resid.w[j] <- y[j,5]-fit.w[j]
# squares of residuals of weight
ssr.w[j] <- pow(resid.w[j],2)
# squares of predicted value of weight
ssr.Pw[j] <- pow((Y.pred[j,2]-y[j,5]),2)
}#end of N
# sum of squares of residuals of height
SSR.h <- sum(ssr.h[])
SSRP.h<- mean(ssr.Ph[])
# EPD of height
# sum of squares of residuals of weight
SSR.w <- sum(ssr.w[])
SSRP.w<- mean(ssr.Pw[])
# EPD of weight
# Prior distributions of the hyperparameters
#(1) Coefficients
for(k in 1:4){theta[k] ˜dnorm(0,0.01)}
for(k in 1:4){beta[k] ˜dnorm(0,0.01)}
for(k in 1:6){alpha[k] ˜dnorm(0,0.01)}
for(k in 1:2){gamma1[k]˜dnorm(0,0.01)}
for(k in 1:2){gamma2[k]˜dnorm(0,0.01)}
#(2). Variance-covariance matrice for model error
Omega1[1:2,1:2] ˜dwish(R1[,],3)
v1[1:2,1:2] <- inverse(Omega1[,])
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#(3) Variance-covariance matrix for random-effects vector
Omega[1:4,1:4]˜dwish(R[,],5)
v[1:4,1:4]<-inverse(Omega[,])
#(4) Skewness parameters
delta1˜dnorm(0,0.01)
delta2˜dnorm(0,0.01)
}
## End of model
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Appendix B
R and WinBUGS program code for MVJM in Chapter 4

## WinBUGS program code named Chapter4-SN.txt
#####################################################################
#### R program code
#####################################################################
library(arm)
library(R2WinBUGS)
data<-list(......)
inits<-list() # Run three chains
inits[[1]]<-list(......)
inits[[2]]<-list(......)
inits[[3]]<-list(......)
parameters<-c(......)
PBC_MVJM_SN <-bugs(data, inits, parameters, "PBC_MVJM_SN.txt",
n.chains=3,
n.thin=20, n.iter=30000,n.burnin=10000,bugs.seed=654321,
bugs.directory="C:\\Users\\WinBUGS14",DIC=TRUE,debug=TRUE)
#####################################################################
#### Start WinBUGS code: hw.t1d.BVJM_SN.txt
#####################################################################
model {
for (i in 1:n)
# n total number of subjects
{
# random effects for bivariate model with normal distribution
for (k in 1:6)
{ b1[i,k] <- 0}
b[i,1:6] ˜ dmnorm(b1[i,1:6],Omega[,])
## individual parameters
beta11[i] <- beta[1]+b[i,1]
beta21[i] <- beta[2]+b[i,2]
beta31[i] <- beta[3]+b[i,3]
beta41[i] <- beta[4]+b[i,4]
beta51[i] <- beta[5]+b[i,5]
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beta61[i] <- beta[6]+b[i,6]
} #End of i
## (1) Event time models(cox regression model)-- occurrence of dead
for(i in 1:n)
# set up data
{
for(j in 1:Tnum)
{
# risk set = 1 if obs.t >= t
risk[i,j] <- step(obs.t[i] - t[j] + eps)
# counting process jump = 1 if obs.t in [ t[j], t[j+1] )
dN[i, j] <- risk[i, j] * step(t[j + 1] - obs.t[i] - eps)*fail[i]
}
}
# Cox regression model
for(j in 1:Tnum)
{
for(i in 1:n)
{
dN[i, j] ˜ dpois(Idt[i, j])
# Likelihood
Idt[i, j] <- risk[i, j] * exp(theta[1]*beta11[i]+theta[2]*beta21[i]+
theta[3]*beta31[i]+ theta[4]*beta41[i]+theta[5]*beta51[i]+
theta[6]*beta61[i]+alpha[1]*T[i,3]+
alpha[2]*T[i,4]+alpha[3]*T[i,5]+
alpha[4]*T[i,8]+alpha[5]*T[i,10]+
alpha[6]*T[i,15])*dL0[j]
}
# Intensity
dL0[j] ˜ dgamma(mu0[j], c0)
mu0[j] <- dL0.star[j]*c0
# prior mean hazard
}
#####coefficients
c0 <- 0.1
r <- 5
for (j in 1 : Tnum) { dL0.star[j] <- r * (t[j + 1] - t[j]) }
for(j in 1:N)
# N=total number of longitudinal measurements
{
## (2) Modelling bivariate longitudianl model
wh[j,1]<-beta11[y[j,1]]+beta21[y[j,1]]*y[j,6]+gamma1[1]*y[j,6]*y[j,6]
+ gamma2[1]*y[j,5]
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wh[j,2]<-beta31[y[j,1]]+beta41[y[j,1]]*y[j,6]+gamma1[2]*y[j,6]*y[j,6]
+gamma2[2]*y[j,5]
wh[j,3]<-beta51[y[j,1]]+beta61[y[j,1]]*y[j,6]+gamma1[3]*y[j,6]*y[j,6]
+gamma2[3]*y[j,5]
#y[j,1]=id, y[j,6]=years, y[j,5]=female
##SN-disctribution
w[j] ˜ dnorm(0, 1) I(0,)

##SN

mean.wh[j,1]<-wh[j,1]+delta1*(w[j]-0.798)
mean.wh[j,2]<-wh[j,2]+delta2*(w[j]-0.798)
mean.wh[j,3]<-wh[j,3]+delta3*(w[j]-0.798)
y[j,10:12]˜dmnorm(mean.wh[j,1:3], Omega1[,])
Y.pred[j,1:3]˜dmnorm(mean.wh[j,1:3], Omega1[,])
#Fitted values and residuals
fit.h[j]
<- mean.wh[j,1]
resid.h[j] <- y[j,10]-fit.h[j]
sresid.h[j] <- sqrt(Omega1[1,1])*resid.h[j]
ssr.h[j] <- pow(resid.h[j],2)
ssr.Ph[j] <- pow((Y.pred[j,1]-y[j,10]),2)

fit.w[j]
<- mean.wh[j,2]
resid.w[j] <- y[j,11]-fit.w[j]
sresid.w[j] <- sqrt(Omega1[2,2])*resid.w[j]
ssr.w[j] <- pow(resid.w[j],2)
ssr.Pw[j] <- pow((Y.pred[j,2]-y[j,11]),2)
fit.x[j]
<- mean.wh[j,3]
resid.x[j] <- y[j,12]-fit.x[j]
sresid.x[j] <- sqrt(Omega1[3,3])*resid.x[j]
ssr.x[j] <- pow(resid.x[j],2)
ssr.Px[j] <- pow((Y.pred[j,3]-y[j,12]),2)
}#end of N
SSR.h <SSRP.h<SSR.w <SSRP.w<SSR.x <-

sum(ssr.h[])
mean(ssr.Ph[])
sum(ssr.w[])
mean(ssr.Pw[])
sum(ssr.x[])
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SSRP.x<- mean(ssr.Px[])
# Prior distributions of the hyperparameters
#(1) Coefficients
for(k in 1:6){theta[k] ˜dnorm(0,0.01)}
for(k in 1:6){beta[k] ˜dnorm(0,0.01)}
for(k in 1:6){alpha[k] ˜dnorm(0,0.01)}
for(k in 1:3){gamma1[k]˜dnorm(0,0.01)}
for(k in 1:3){gamma2[k]˜dnorm(0,0.01)}
#(2). Variance-covariance matrice for model error
Omega1[1:3,1:3] ˜dwish(R1[,],3)
v1[1:3,1:3] <- inverse(Omega1[,])
#(3) Variance-covariance matrix for random-effects vector
Omega[1:6,1:6]˜dwish(R[,],7)
v[1:6,1:6]<-inverse(Omega[,])
#(4) Skewness parameters
delta1˜dnorm(0,0.01)
delta2˜dnorm(0,0.01)
delta3˜dnorm(0,0.01)
}
## End of model
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